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Investigate changes in retinal structure and function caused by multiple sclerosis (MS) using 
established and novel modes of image acquisition and analysis, in order to identify candidate 
biomarkers of disease. Use longitudinal analysis to determine the rate at which changes to the 
retinal anatomy occur and whether this rate-of-change alters throughout the MS disease 
course.  
Method  
Within the Anne Rowling Regenerative Neurology Clinic (Royal Infirmary of Edinburgh), 72 
MS participants (53 female, 19 male, age range 20-79, median age 44) and 80 healthy 
volunteers (HV) (61 female, 19 male, age range 23–73, median age 38) received spectral 
domain optical coherence tomography (SD-OCT) and ultra-wide field scanning laser 
ophthalmoscope (UWF-SLO) scans at baseline. Within the MS group, 16 (9 right eyes and 10 
left eyes) had at least one clinically diagnosed episode of optic neuritis (ON). Follow up scans 
were taken at approximately 3, 6 and 12-month intervals over the course of two years. Visual 
acuity (VA) as an indicator of retinal function was also measured at each visit using Sloan 
letter charts at 100% and 2.5% illumination.  
Through proprietary software, automatic segmentation of SD-OCT images quantified changes 
to retinal nerve fibre layer (RNFL) thickness and macular volume. Novel image processing 
algorithms specifically adapted to semi-automatically segment the vasculature in UWF-SLO 
images (using multi-scale filtering and supervised classification) allowed for measurement of 
vessel diameter. Data from the 3 participant groups (MS (no ON), MS (ON) and HV) was first 
tested statistically for significant differences. Linear regression modelling with the inclusion 
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of disease, sex, length-of-disease and age as predictors was then used to estimate the true 
effects of disease on the retinal anatomy without confounders.  
Results  
Baseline data showed that individuals with MS (no ON) have a reduced RNFL thickness in all 
peripapillary regions and a reduced macular volume when compared with HVs. The reduction 
in RNFL thickness was seen globally in both eyes (OS: -10µm, OD: -11µm, p<0.001) but was 
greatest in the inferior temporal region (OS: -15µm, OD: -13µm, p<0.01). In the MS (ON) 
group the reduction in RNFL thickness was even greater, again being largest in the inferior 
temporal region (OS: -29µm, OD: -24µm). Linear regression models confirmed the effect of 
disease on RNFL thickness and macular volume with significant coefficients in all regions but 
the inferior nasal. Follow-up analysis showed that the MS (no ON) group had a larger annual 
rate-of-thinning of the RNFL than HVs in the majority of regions, the largest difference being 
in the inferior nasal (OS: -1.32µm/year, OD: -1.06µm/year, p<0.05) and superior nasal (OS: -
1.11µm/year, OD: -1.13µm/year, p<0.05) regions. 
Retinal arteries were shown to have a significantly reduced diameter in only the inferior nasal 
quadrant, where the greatest reduction in vessel width was found (OS: -0.005mm, OD: -
0.007mm, p<0.05). For mean venous width, the inferior nasal quadrant of the right eye also 
showed a statistically significant difference between the two groups (OS: -0.005mm, OD: -
0.005mm). Linear regression models were more frequently significant for arterial rather than 
venous data, despite both vessel types having significant disease coefficients in the inferior 
nasal quadrant. Follow-up data was inconclusive on the effect that disease has on the annual 
rate-of-change of vessel thinning. 
Median baseline high contrast VA (OS: -6, OD: -3, p< 0.05) and low contrast VA (OS: -6, 
OD: -6, p<0.01) scores were significantly reduced in the MS (no ON) group when compared 
to HVs. In this study, MS seemed responsible for a 1 line drop in both high contrast and low 
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contrast VA scores in the MS (no ON) group. A significant difference between the HV group 
and MS (ON) group was only found in the median low contrast VA score of the left eye (OS: 
-21, OD: -4, p< 0.05). As with vessel analysis, follow-up data showed no significant rates-of-
change in VA score.  
Conclusions   
At baseline, the RNFL and blood vessels of the retina were significantly thinner in the MS (no 
ON) group when compared to HVs in particular regions. Consistent with previous reports in 
the literature, both RNFL and macular volume showed a significant decrease in individuals 
with MS (no ON). However, this is the first study to show that both arteries and veins in the 
retinal periphery also have a reduced width in the inferior nasal quadrant. Such changes in the 
retinal anatomy correlate with a drop in visual function as measured by VA. 
An increased annual rate of RNFL thinning was also seen in participants with MS (no ON) 
indicating that anatomical changes occur over time rather than acutely, however this rate-of-
change is largest early in the disease course. A similar pattern was observed with the rate at 
which macular volume decreases in individuals with MS (no ON). Whether changes to the 
retinal blood vessels occur over time was not determinable within this study, due to the effect 
size being too small for the number of participants recruited. Future studies should focus on 
replicating findings pertaining to retinal blood vessels and determining when in the MS disease 




My research looks at whether images of the back of the eye could be used to identify the early 
signs of multiple sclerosis (MS) and better understand its initial stages. MS is a chronic illness 
most commonly diagnosed in people between the ages of 20 and 50, which causes an 
individual to become progressively more disabled as the disease advances. It is characterised 
by a gradual decrease in one’s ability to control movement as the nerves, which form a network 
transmitting signals from the brain and spinal cord to muscles throughout the body, are 
damaged over time. MS affects more than 2.3 million people worldwide, reducing average life 
expectancy by 7 years and potentially ending with paralysis. An individual’s symptoms can 
vary widely making both diagnosis and prognosis potentially difficult. This is problematic as 
for an individual to derive the greatest benefit from a treatment, it is important they are 
diagnosed as early as possible. Even with an early diagnosis, there is no known cure and there 
are some types of the disease for which there are no successful treatments. The causes of MS 
are not yet known but it is thought that a breakdown of the protective lining of the brain (the 
blood-brain barrier), which filters out cells from within the blood and prevents them from 
entering the brain, could partially be to blame. A more complete understanding of the disease 
could help make better use of existing drugs, aid the development of new treatments and offer 
early detection methods for patients before the onset of any severe symptoms. Specifically, 
the question as to whether blood vessels or nerves are the first to be affected is important in 
understanding the initial stages of MS.  
 
Retinal scanning offers researchers an inexpensive and patient-friendly method of measuring 
the thickness of blood vessels and nerves in the back of the eye (the retina) much more 
precisely than other imaging methods such as magnetic resonance imaging (MRI). The retina 
is linked directly to the brain via the optic nerve and as such, it is considered an extension of 
the body’s network of nerves (known as the central nervous system) and shares structural 
similarities with the brain; much as the brain is affected by MS, so are the nerves within the 
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retina. By measuring the thickness of these nerves with the help of computer software, 
previous studies have shown how the retina can be used to reveal the damage done by MS. 
However, studies looking at changes in retinal blood vessels in patients with MS are scarce, 
despite the retina having a blood-tissue barrier similar to that of the brain- which is thought to 
be breached early in the disease course. Over a two-year time period, I investigated changes 
to the retina in MS by imaging people with the disease and comparing these scans with those 
taken from healthy volunteers within the Anne Rowling Regenerative Neurology Clinic, 
Edinburgh. Using two different retinal scanning devices and specialised image analysis 
techniques, I was able to measure the width of retinal nerves and blood vessels at the back of 
the eye and track any changes over time. I also used a series of letter charts to measure each 
participant’s visual function and determine how changes to nerves and blood vessels can affect 
an individual’s ability to clearly view fine details (known as visual acuity).  
 
My results support previous findings that the retina’s nerve layer is thinner, and therefore more 
damaged, in people with MS. This difference in thickness acts as an indication of disease 
activity. I also found that changes to the retinal nerves occur gradually over the MS disease 
course, with the largest changes happening early-on and slowing down over time. 
Furthermore, this study has shown for the first time ever that within specific regions of the 
retina, both arteries and veins have a reduced width in individuals with MS. Although, whether 
these changes to the blood vessels occur gradually over time or only happen early in the disease 
course could not be adequately concluded. These findings are relevant to an individual’s 
everyday life, for with these changes there comes a fall in retinal function (i.e. ability to resolve 
fine details) as measured by letter charts throughout the study.  
 
My results contribute knowledge relating to the effects of MS on the retinal blood vessels and 
as such, should encourage future studies to further investigate these changes. Future work 
should focus on confirming when retinal changes occur in the disease course of MS and 
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whether retinal scanning can help identify those patients who are most at risk of developing 
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List of abbreviations  
 
 
A-scan  axial scan 
ARRNC Anne Rowling Regenerative Neurology Clinic 
ART  automatic real time 
B-scan  2D image created from A-scans 
BBB  blood-brain barrier 
BRB  blood-retina barrier 
CI  confidence interval 
CNS  central nervous system 
CSF  cerebrospinal fluid 
DIS  dissemination in space 
DIT  dissemination in time  
EDSS  enhanced disability status score 
ETDRS  Early Treatment Diabetic Retinopathy Study  
FOV  field of view  
FS  functional symptom  
G  global 
HCVA  high contrast visual acuity 
HV  healthy volunteer 
ICC                   intraclass correlation coefficient 
IQR  interquartile range 
LCVA  low contrast visual acuity  
MRI  magnetic resonance imaging    
MS  multiple sclerosis  
MSFC  multiple sclerosis functional composite  
MS (no ON) multiple sclerosis without clinical history of optic neuritis  
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MS (ON) multiple sclerosis with a clinical history of optic neuritis  
N  nasal 
NI  nasal inferior  
NS  nasal superior  
OCT  optical coherence tomography  
OD  right eye 
ON  optic neuritis  
OS  left eye  
PMB  papillomacular bundle  
PPMS  primary progressive multiple sclerosis  
PRMS  progressive relapsing multiple sclerosis  
RGC  retinal ganglion cell 
RNFL  retinal nerve fibre layer  
ROI  region of interest 
RPE  retinal pigment epithelium  
RRMS  relapse remitting multiple sclerosis  
SD  spectral domain 
SD-OCT spectral domain optical coherence tomography  
SE  standard error 
SLO  scanning laser ophthalmoscope  
SNR  signal-to-noise ratio 
SPMS  secondary progressive multiple sclerosis  
T  temporal 
TD-OCT time domain optical coherence tomography  
TI  temporal inferior 
TS  temporal superior  
UWF-SLO ultra-wide field scanning laser ophthalmoscope  
VA  visual acuity  
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The use of retinal imaging to identify anatomical changes caused by multiple sclerosis (MS) 
has shown evidence to support its use as a tool to track disease activity. Previous studies have 
largely focused on analysing data from optical coherence tomography (OCT) images, which 
quantifies changes to the central nervous system that may act as surrogates for similar changes 
in the brain. Studies that analyse changes to the retinal vasculature are scarce in comparison, 
and as such the understanding of how MS affects the retinal vasculature is under investigated. 
MS patients may stand to benefit from studies which focus on changes to blood vessels in the 
retina, as they could develop our understanding of the initial disease mechanisms and aid in 




A longitudinal cohort study was planned to address the following three hypotheses: 
1. An individual diagnosed with MS will have quantifiable differences to their retinal 
vasculature at baseline imaging compared to healthy controls 
2. An individual diagnosed with MS will have quantifiable differences to their RNFL 
thickness and macular volume as measured by OCT 
3. An individual diagnosed with MS will have quantifiable changes to their retinal 




1.3 Thesis outline  
In chapter 2, I will describe the relevant pathology and epidemiology of MS, highlighting the 
importance of early diagnosis and the current difficulties with diagnosis and accurate 
prognosis.  The anatomy of the retina is then considered alongside a summary of findings from 
previous studies which provide evidence for how the retina is affected by MS. Chapter 3 
continues by describing the imaging techniques which are used during this study (OCT, ultra-
widefield scanning laser ophthalmoscope (UWF-SLO)) with the technical details of each 
device, alongside information on visual acuity (VA) and its use in measuring retinal 
functionality.  How each of these methods were used to answer the hypotheses set out in 
chapter 1.2 are described in detail in chapter 4 as I lay out the methodology behind patient 
recruitment, image analysis and acquisition and the statistical methods used. Analysis of the 
data will be divided into two distinct chapters: baseline (chapter 5) and longitudinal (chapter 
6). Both chapters will follow the same pattern of analysis as participant groups are first 
compared through Student’s t-test or Mann-Whitney U test, and then compared through the 
use of linear regression models. Finally, the discussion in chapter 7 will detail the limitations 
of the data collected, interpret the results, place them in the context of previous studies and 









Chapter 2  
Multiple Sclerosis and the Retina 
2.1 Introduction 
MS is a chronic neurodegenerative disease; with over 2.3 million sufferers worldwide (1), it 
is the most common cause of non-traumatic neurological disability in young adults (2). A 
quick diagnosis of MS is essential for patient care, however many of the symptoms are not 
specific only to MS (3). The diagnostic procedure may be prolonged as it frequently relies on 
expensive magnetic resonance imaging (MRI) procedures to view the central nervous system 
(CNS) as well as clinical assessments, such as blood tests and assessments of cognitive and 
motor function. The advent of a novel technique which could help diagnose and prognose MS 
at an early stage would help improve current clinical practice and benefit patients who could 
receive disease-modifying treatments earlier. 
 
2.2 Multiple sclerosis  
2.2.1 Pathology 
Fundamentally the CNS is a collection of neurons (see Figure 2.1): specialized nerve cells that 
relay electrical potentials from sensory receptors to effector organs. Neurons comprise a cell 
body containing a nucleus, around which are typically several dendrites that receive signals 
from surrounding neurons. A single axon stretches out from the cell body and is responsible 
for relaying impulses to adjacent neurons.  To increase the speed of this process, the axon is 
surrounded by a myelin sheath. This fatty layer insulates the axon enabling an action potential 
to travel from one node to another at a higher velocity than would otherwise be possible 
(conduction velocity in myelinated fibres 5-120 m/s compared to unmyelinated fibres 0.5-2.5 
m/s) (4).  
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MS is characterised by demyelination of the axon and its eventual degeneration. A 
comprehensive understanding of the disease’s cause has yet to be attained, but it is thought 
that both genetics and environmental factors contribute to onset (3). Pathogenetically, the 
disease develops due to immunopathological responses within the CNS; one of the earliest 
manifestations of MS is a migration of autoreactive lymphocytes through the blood-brain 
barrier (BBB) (5) (6) (7).  
Though increased permeability of the BBB is not unique to MS, it may be responsible for the 
initial inflammation which in turn causes the formation of sclerotic plaques after 
demyelination (6). The subsequent plaques impede rapid electrical conduction through 
individual axons- the drivers of motor functions. Spontaneous remyelination does occur to a 
limited extent within the CNS leading to periods of remission, but its success differs between 
individuals and can be short-lived (8). The question as to whether inflammation is indeed a 
precursor to neurodegeneration has yet to be definitively answered- it is possible that 
inflammation is a secondary response to neurodegeneration (6).  
Figure 2.1: Diagram of a neuron, showing the axon surrounded by a myelin sheath (101) 
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2.2.2 Epidemiology  
Environment undoubtedly plays an important role in the cause of MS but the extent to which 
is yet unclear (9). A decrease in mortality rates in the UK has seen a statistical increase in the 
prevalence of MS, however a study on incidence between 1990 and 2010 showed a downward 
trend in new cases of MS being diagnosed in the UK. This may be due to better diagnosis 
resulting in fewer false positives (10). The typical age of onset is between 20 and 50 years (9). 
MS disproportionally affects women, with a mean female-to-male ratio of 2.4 (10). Studies on 
the distribution of MS rates worldwide show a general increase in prevalence with a greater 
distance from the equator, with the highest rates being in Orkney and the Shetland Isles (11). 
As such, it is thought that vitamin D deficiency may be a contributing factor in higher rates of 
MS. 
Genetics also contributes to the incidence of MS (9). Individuals with close family members 
who suffer from MS show an increased incidence, denoting a positive correlation between 
genetic sharing and lifetime risk of developing the disease (6). 
2.2.3 Diagnosis and prognosis  
Though 95% of patients with MS show white matter abnormalities on MRI of the brain and 
spinal cord, this is not adequate for a diagnosis; diagnosis is not determined by a single test 
(e.g., cerebrospinal fluid (CSF) analysis) or clinical feature, but through clinical assessment 
(6) (12) (3). The 2010 McDonald criteria (see table 2.1) for diagnosis of MS requires 
“objective clinical evidence of 2 lesions or objective clinical evidence of 1 lesion with 
reasonable historical evidence of prior attack” for a diagnosis without need of any additional 
information (12) (13). As such, correct diagnosis can be a long and frustrating ordeal for the 
patient as successive symptoms may have large periods of time between them.  
Once diagnosed, patients are grouped into one of four disease subtypes through patient history 
and examination: primary progressive (PPMS), secondary progressive (SPMS), relapse and 
remitting (RRMS) and progressive relapsing (PRMS).  Each of these subtypes progress in a 
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different manner, as is displayed in Figure 2.2. The frequency and severity of attacks within 
the initial stages of the disease are considered fair indicators of how quickly the disease will 
progress in the future (3). In 85-90% of cases, a patient will first experience RRMS 
characterised by cycles of acute attack and recovery. Difficulties can occur in disease 
categorisation as patients will often make the transition from RRMS to more progressive forms 
(65% within 25 years) (3). Several disease-modifying treatments are available for non-
progressive sufferers, which for the most part aim to reduce inflammation (14). Clinical trials 
have shown both first and second line therapies to be effective against placebo at reducing 
disability progression in patients with RRMS (14). Treatments are not without their side-
effects, one example being fingolimod which is associated with an increased risk of macular 
oedema (15). 
Quick intervention has been shown to be more effective for the prevention of disease 
progression, suggesting long-term damage to axons is reduced when the time spent subjected 
to early inflammatory responses is reduced (16). Additionally, there is also suggestion that 
patients who receive treatment at disease presentation derived greater benefit from later 
treatments than those who waited a period of two years before intervention (17). Uncertain 
prognosis becomes troublesome when deciding which treatment, therapy and potency is best 
suited to a patient. Currently, no disease-modifying treatments have proven effective on 
progressive disease onset.  
Clinically, SPMS would be diagnosed after a “period of sustained deterioration in neurological 
function without remission” of roughly six months, as then the likelihood of reversibility of 
symptoms becomes small (3). As displayed in Figure 2.2, independent of previous disease 
course the progression of symptoms appears to occur at a steady rate in patients with SPMS, 
rather than in periods of relapse. Such a diagnosis may only be possible after retrospectively 




   
Clinical Presentation Additional Data Needed for MS Diagnosis  
≥2 attacks; objective 
clinical evidence of ≥ 2 
lesions or objective clinical 
evidence of 1 lesion with 
regional historical 
evidence of a prior attack 
None 
≥2 attacks; objective 
clinical evidence of 1 
lesion 
Dissemination in space (DIS), demonstrated by: 
≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial or spinal cord); 
or await a further clinical attack implicating a different CNS 
site 
1 attack; objective clinical 
evidence of ≥ 2 lesions 
Dissemination in time (DIT), demonstrated by: 
Simultaneous presence of asymptomatic gadolinium-
enhancing and nonenhancing lesions at any time; or a new 
T2 and/or gadolinium-enhancing lesion(s) on follow-up 
MRI, irrespective of its timing with reference to a baseline 
scan; or await a second clinical attack 
1 attack; objective clinical 
evidence of 1 lesion 
(clinically isolated 
syndrome) 
Dissemination in space and time, demonstrated by: 
For DIS: 
≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial or spinal cord); 
and 
For DIT: 
Simultaneous presence of asymptomatic gadolinium-
enhancing. A new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI, await second clinical attack 
 
Insidious neurological 
progression suggestive of 
MS (PPMS) 
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the following 
criteria; 
1. Evidence for DIS in the brain based on ≥1 T2 
lesions in the MS-characteristic (periventricular, 
juxtacortical or infratentorial) regions 
2. Evidence for DIS in the spinal cord based on ≥2 T2 
lesions in the cord 
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index) 
 
Table 2.1: 2010 Macdonald criteria for diagnosis of MS, showing the additional clinical 
data required for a diagnosis given each clinical presentation (12) 
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Both progressive forms of MS can manifest themselves through spinal cord dysfunction- 
evidence for which can be presented as lesions on the spinal cord as shown with MRI and 
associated symptoms e.g., lower limb dysfunction. PPMS diagnosis differs from SPMS as the 
time from disease onset to advanced disability has been shown to be shorter (3). However, 
progression of the disease is similar to that of SPMS. 
Although the disease is not fatal, the increased prevalence of infection and illnesses related to 
immobility reduces life expectancy by a mean of seven years; from time-of-diagnosis the 
median time to death is thirty years and in 2/3 of cases MS is the attributable cause of death 
(6). Despite categorising an individual’s MS into one of four subtypes, progression of the 
disease is widely variable between individuals (3). Though some patients with MS will have 
relatively benign cases, quality of life is invariably affected as symptoms include cognitive 
impairment, pain, fatigue, bladder dysfunction, loss of vision and poor balance. Furthermore, 
individuals with MS are three times more likely to suffer from depression when compared 
with the general population, though it is unclear whether this is driven by psychological or 
mechanistic factors (18). 
The Expanded Disability Status Score (EDSS) is an attempt to quantify how severely disabled 
a patient is due to MS. Measurements are made of impairment in eight functional symptoms, 
including bowel and bladder function and weakness in limbs (19). For each of these, a score 
is given, with an additional score for impairment of the ability to walk. A score of zero 
represents no disability, whereas scores of six or above indicate severe disability. Despite 
being the most widely used tool by neurologists to stratify patients during clinical assessment, 
the EDSS lacks sensitivity to change (20).  As such, competing tools e.g., Multiple Sclerosis 
Functional Composite (MSFC) have been increasingly used in clinical trials to offer a 
multidimensional metric with which to assess clinical status (20). Such tools may include a  
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Figure 2.2: Disease progression in MS: a) RRMS, where we see the cycles of attack 
and full recovery b) PPMS shows a constant increase in disease severity in B1, and a 
steady increase in B2 but with periods of improvement c) SPMS where RRMS is 
followed by a progression of disease with periods of acute attack in C2 and without 
in C1 d) PRMS with acute attacks but with periods of slight recovery in D1 and 






1 No disability, minimal signs in one FS. 
1.5 No disability, minimal signs in more than one FS. 
2 Minimal disability in one FS. 
2.5 Mild disability in one FS or minimal disability in two FS. 
3 Moderate disability in one FS, or mild disability in three or four FS. No impairment to walking. 
3.5 Moderate disability in one FS and more than minimal disability in several others. No impairment to walking. 
4 Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m. 
4.5 
Significant disability but up and about much of the day, able to work full day, 
may otherwise have some limitation of full activity or require minimal 
assistance. Able to walk without aid or rest for 300m. 
5 Disability severe to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m. 
5.5 Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m. 
6 Requires a walking aid – cane, crutch, etc. – to walk about 100m with or without resting. 
6.5 Requires two walking aids- pair of canes, crutches, etc. – to walk about 20m without resting. 
7 
Unable to walk beyond approximately 5m even with aid. Essentially restricted 
to wheelchair; though wheels self in standard wheelchair and transfers alone. 
Up and about in wheelchair some 12 hours a day 
7.5 
Unable to take more than a few steps. Restricted to wheelchair and may need 
aid in transferring. Can wheel self but cannot carry on in standard wheelchair 
for a full day and may require a motorised wheelchair. 
8 
Essentially restricted to bed or chair or pushed in wheelchair. May be out of 
bed itself much of the day. Retains many self-care functions. Generally has 
effective use of arms 
8.5 Essentially restricted to bed much of the day. Has some effective use of arms and retains some self-care functions.  
9 Confined to bed. Can still communicate and eat. 
9.5 Confined to bed and totally dependent. Unable to communicate effectively or eat/swallow. 
10 Death due to MS. 
Table 2.2: EDSS definitions. Functional symptoms (FS) are distinguished as: 
pyramidal, cerebellar, brainstem, sensory, bowel and bladder function, visual function, 
cerebral functions and other (100) 
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2.3 The Retina 
The retina comprises the inner most layers of the eye. Not only does the retina directly link to 
the brain via the optic nerve, but it is considered an extension of the CNS (21). In embryonic 
development, the retina develops in tandem with the optic nerve as an extension of the 
diencephalon and as such they share a great deal in common with respect to anatomy, 
pathology and physiology (4). It is therefore argued that changes to the retina may act as 
valuable surrogates for changes which also occur within the brain (22).   
 




Figure 2.3: A diagram of the human eye, showing the internal structures and their 
location. At the rear of the eye, we see the retina and its supply of blood vessels, 
both of which converge at the optic nerve (24) 
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The eye’s inner surface, or retina, is responsible for turning images acquired from external 
stimuli into neural impulses to be processed in the brain. It comprises an axonal layer above 
multiple different cell layers (see Figure 2.4). As light enters the pupil, it is refracted by the 
lens and converges on the fovea- an area on the retina which is densely populated with cone 
cells (one of two types of photoreceptors).  
A process of visual phototransduction then occurs, where the incident light signal is converted 
to a neural impulse and sent via bipolar cells to the retinal ganglion cells (RGCs)- neurons 
formed to create the innermost cellular layer) (4). The axons of these cells bundle together to 
from a layer of unmyelinated tissue known as the retinal nerve fibre layer (RNFL). This layer 





Figure 2.4: A diagram of the retinal cell layers, the RNFL being closest to the 
surface of the retina (24) 
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The optic disk can be identified as the bright circular spot in an image of the retina (see Figure 
2.5). It is the location to which nerve fibres converge and form the optic nerve that passes 
through the sclera at the rear of the eyeball (23). The optic nerve acts as the information 
highway, channelling electrical charge between the lateral geniculate body and the eye (4). 
Whereas the neurons found in the retina resemble that of grey matter within the brain, the optic 
nerve itself is composed of white matter. As such, it is not a peripheral nerve but rather part of 
the CNS (4) (24). 
Another structural similarity to the brain is the blood-retina barrier (BRB). Acting as a 
regulator for the passage of immune cells and pathogens within the retinal pigment epithelium 
(RPE), it protects neurons within the retina much as the BBB does in the brain (21) (23). Blood 
flow to the retina occurs via two sources: the choroid oxygenates the photoreceptors and outer 
layers of the retina, whereas the inner layers are supplied by blood vessels which emanate 
outwards from the optic disk all the way into the periphery of the retina (see Figure 2.5) (4).  
Figure 2.5: Fundus camera image of the retina in a left eye. As described, the bright 
circular spot is the optic disk, from which the blood vessels spread out to the periphery 
of the retina. The dark spot to the right of the optic disk is the macular, at the centre of 
which lies the foveal dip. 
 
 14 
2.3.2 How MS affects the retina 
Ophthalmological problems are very commonplace in MS: in 20% of cases optic neuritis (ON) 
is the presenting symptom (25). ON is an inflammatory demyelinating disease of the optic 
nerve and is reported in 75% of MS patients at some point during their life (21). The disease 
strips myelin from the optic nerve- causing poor conduction and subsequent damage to the 
axons of the optic nerve and RNFL.  Patients with ON complain of a painful temporary loss 
or impairment of vision in one eye (26). The footprints of ON remain even once visual function 
is restored: during ON, oedema causes the RNFL to swell in thickness which leads to a 
significant thinning of the RNFL (as measured via OCT- see chapter 3). In a meta-analysis of 
2,063 eyes a mean RNFL thickness reduction of 20μm was measured using time domain OCT 
(TD-OCT) in patients with a history of ON, corresponding to a 20% reduction in thickness 
(27).  
MS patients without history of a clinical episode of ON also show a loss in RNFL thickness 
over time (again measured with TD-OCT, 3.4mm circumferentially around the centre of the 
optic disc), though it is smaller than that expected after an episode of ON (28) (27). Another 
meta-analysis, this time of 3,100 eyes, found a mean RNFL reduction of 7μm was found in 
MS patients who had never reported a clinical episode of ON, whilst a large multi-centre study 
using spectral domain OCT (SD-OCT) on 414 MS patients measured a global reduction of 
10µm (29). Macular volume has also been shown to decrease in patients with MS; a study of 
530 participants found a 2.9% reduction in total macular volume (the sum of the volumes of 
the neural retina in the central 6mm of the macula) when comparing MS patients to healthy 
controls in both eyes using TD-OCT (30). When relating macular volume to RNFL thickness, 
the same study found that a 10µm reduction in RNFL thickness corresponded with a 0.2mm3 
reduction in macular volume (30). Patients in this study had their pupils dilated using 
tropicamide, 1%, when necessary (<5mm) as well as a patch placed over their non-tested eye. 
When considering the peripapillary quadrants individually, the most significant changes occur 
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in the temporal region. RNFL changes are greater temporally to the extent that studies have 
differentiated between SPMS and PPMS patients using temporal RNFL thickness reductions 
alone (31). Moreover, focal defects are exclusively located in the temporal region of the retina 
(32).  As such, it seems that the temporal retina is more severely affected by MS than other 
regions.  Furthermore, thinning of the RNFL and macular appears to occur gradually as the 
disease progresses. A study of 135 patients with MS (median disease duration of 16.4 years, 
68% of which were diagnosed as having RRMS) were imaged over a period of two years and 
had a global RNFL thinning of 1.1µm over this period of time as measured with SD-OCT (33). 
The same study also included 16 healthy volunteers (HVs) who showed a thinning in the RNFL 
of -0.5µm over a two-year period, indicating that RNFL thinning occurs at a greater pace than 
in patients with MS than in HVs (33).  
Similarly, a study of 299 patients with MS scanned at regular 6-month intervals showed a 
global RNFL thinning of 2.9µm in 2 to 3 years and a 6.1µm loss in 3 to 4.5 years using TD-
OCT (34). This study again used a protocol of pupil dilation when necessary (pupils <5mm) 
and a patch placed over the non-tested eye. Finally, a study which imaged 34 MS patients (16 
PPMS, 18 SPMS) over a median time of 575 days showed no significant changes using TD-
OCT, but nevertheless a global reduction of 0.99µm annually (35). The study also saw a 
0.038mm3 (p = 0.013, 95% CI -0.067, -0.008) reduction in macular volume per year in MS 
patients, although it compared with a 0.031mm3 (p = 0.005, 95% CI -0.052, -0.009)) reduction 
seen in 18 HVs most likely as a consequence of aging. Significant age-related declines in 
macular volume and RNFL thickness have been reported in multiple studies, using both SD-
OCT and dissection of HV eyes (36) (37). The effect of age on macular volume is thought to 
be more observable than in RNFL thickness- some studies inferring that this is due  to macular 
volume measures proportionately containing a greater amount of ganglion cells which are 
more at risk of degeneration as a function of age (35). However, this theory is not consistent 
across all histological studies on the subject (36). Despite this, longitudinal imaging of 70 eyes 
over a 30-month period found an approximate -0.52µm/year thinning of the RNFL, largely 
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concentrated in the superior and inferior quadrants (36). 
The rate that the RNFL thins may not be uniform, as was also reported by Balk et al (33). In 
this study, the predictor length-of-disease was categorised it into 6 bins e.g., <5 years, 5-9.9 
years etc. The subsequent modelling showed that neurodegeneration was more pronounced 
early in the disease course whereby every additional year an individual lived with MS resulted 
in a 0.05µm reduction in the thinning of the RNFL over a two-year period. 
Retinal symptoms are not exclusive to the CNS; 10% of patients with MS suffer from retinal 
periphlebitis (RP), a vasculitis of the peripheral retinal vasculature (38). A classic way in 
which this disease presents itself is in perivascular sheathing where blood vessels may appear 
cuffed in a white plaque as inflammatory cells surround affected blood vessels (39).  
Symptoms can include blurred vision, floaters and pain. Research suggests that individuals 
with higher EDSS scores are more likely to suffer from RP, supporting its use as a biomarker 
of disease progression (38). Also, regarding the retinal vasculature: a study of 71 subjects 
which used peripapillary OCT scans (see chapter 3) to measure vessel width at a radius of 
3.4mm from the optic disk found that vessels were significantly thinner in participants with 
MS (40). No attempt was made to classify the vessels as artery or vein or to separate the blood 
vessels into their respective quadrants, and no association between blood vessel diameter and 
a history of ON was found in this cohort.  
Finally, a reduction in the retinal functionality of patients with MS has also been reported, as 
measured by low-contrast visual acuity (LCVA) which itself has been found to correlate with 
axonal and neuronal loss as measured with OCT and changes in EDSS score (41).  Talman et 
al.’s study of 299 patients with MS scanned with a minimum of 6 months between baseline 
and follow-up showed 12% of participants with a drop in high contrast visual acuity (HCVA) 
score of ³5 letters and 13% of participants with a ³7 letter fall in LCVA score. Results for 
individuals with a history of ON were the same for HCVA score but only 12% had a clinically 
significant drop in their LCVA score (42). This study also showed that eyes with the greatest 
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degree of visual loss also showed the thinnest RNFL. However, a study of RRMS patients, 
which imaged 61 participants at baseline and at 6 years follow-up determined that MS 
individuals had a visual acuity score which remained constant, but individuals with a history 
of ON showed a significant drop off in their score (43).  
2.4 Summary 
The difficulty in rapid diagnosis and prognosis of MS presents an obstacle to patients 
benefitting from disease-modifying treatments early in their disease course. The ability to view 
the vasculature and CNS non-invasively through the pupil offers great potential. With its 
structural similarities to the brain, the retina is a versatile site that could enable a greater 
understanding of the pathological and anatomical changes occurring in MS. Changes should 
not be considered in isolation but may prove to be surrogates for similar changes occurring 
within the brain; reduction in RNFL and macular volume are associated with global brain 
atrophy as quantified with MRI (44). Detecting such changes early could offer a more 
comprehensive understanding of the initial mechanisms of the disease (i.e. inflammation and 
neurodegeneration), thus aiding the creation of new targeted treatments and therapies. The 








Retinal Imaging   
3.1 Introduction 
The eye offers an inexpensive, quick and non-invasive method of capturing images of the CNS 
and microvasculature at high resolution via the anterior visual pathways. Images are obtained 
in a matter of seconds and with semi-automatic image analysis algorithms, anatomical 
information can be extracted in vivo without the need for an invasive biopsy. Operators can 
be trained in a short period of time and patients suffer none of the anxiety which may come 
with MRI such as claustrophobia (45). As such, retinal imaging has the potential to play a 
pivotal role in the diagnosis and tracking of neurodegenerative diseases. 
3.2 Optical Coherence Tomography  
Since it was first shown possible to image and segment the retina’s cellular layers and measure 
their thicknesses by Huang et al., OCT has become a hugely popular technique in the field of 
retinal imaging; its high resolution (typically 7μm axially) delivers the ability to make precise 
axonal measurements (46). OCT has helped expand on not only the general understanding of 
how eye diseases develop, but also the role that neurodegenerative diseases play in affecting 
the retina and CNS; studies show a thinning of the RNFL in patients of MS, Parkinson’s and 
Alzheimer’s disease (17) (47) (48) (27). 
OCT is analogous to ultrasound (49). In ultrasound, high frequency ‘pulse’ sound waves are 
transmitted through body tissue (such as the womb of an expectant mother) and an image is 
constructed using measurements of the time taken for these sound waves to echo and return to 
a detector (50). Rather than sound, OCT uses infrared light for a similar purpose. It is when 
detecting the reflected signal that OCT diverges from ultrasound. To observe directly the time 
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taken for light to travel to the retina and back, measurements would have to be made on a 
femtosecond (10-15) scale (51). As this is not currently possible, techniques that rely on 
interferometry are used instead.  
Interferometry exploits the wave nature of light, measuring distances in a sample through the 
coherence of a detected signal with a reference signal (51). A schematic of the process is 
displayed in Figure 3.1. Utilising infrared light (which is more penetrative of the retinal cell 
layers than light of visible wavelengths (52)), the light incident on the beam splitter, Ei, is 
directed fifty-fifty towards a reference mirror and a tissue sample e.g., the retina.  For the 
purposes of explanation, it is useful to use a model with discrete surfaces though in reality the 
sample would be better represented by a continuous function (51). The wave reflected from 
the sample, ES, is a combination of all the waves which have been reflected at the different 
surface boundaries within the sample (51). The reflected wave then interferes with the wave 
ER from the reference mirror, at which point the resulting incidence ray ID propagates towards 
the photodetector (53).  
Figure 3.1: The theory of TD-OCT to image the retinal cell layers. Ei is the incident light beam which is split 
50:50 to the reference mirror, ZR, and the sample (the retina), ZS. ES comprises all the waves reflected from 
retinal cell layer boundaries, ER is the beam reflected from the reference mirror. ID is the beam constructed from 




Early time domain (TD) systems used mechanical changes in the distance between the beam-
splitter and the reference mirror to create an axial scan (A-scan) from the detected signal (51). 
A-scans are representative of a 1-D line of data within an image. To create a 2-D image (B-
scan), A-scans are simply aligned laterally with one another (54). To reduce the signal-to-
noise ratio (SNR) of B-scans allowing for better segmentation of retinal anatomy, scans can 
be averaged, whereby repeat scans of the same region are taken to produce a final composite 
image. The obvious trade-off in acquiring a clearer image is an increase in acquisition time 
(55).  
Superior images are the product of spectral domain (SD) systems, whereby the reference 
mirror is a fixed distance from the beam-splitter (54). In such setups, the photodetector is 
replaced by a spectrophotometer which records spectral domain signals from the incident ray, 
ID, having first passed through a diffraction grating (53). To acquire an A-scan, the SD signal 
must be transformed into a spatial domain signal- a Fourier transform is used to achieve this 
(51) (56). 
As SD-OCT is free from the limitations that come with the moving reference arm used in TD-
OCT, A-scan acquisition rate improves from approximately 400/s to 29,000/s, allowing B-
scans to be taken in just 1/29s (27) (54). Using this method, greater optical resolutions of 7μm 
axially and 14μm laterally can be made with a SD-OCT machines (see Figure 3.2) (57). Faster 
acquisition also allows SD-OCT to take scans both of volume and a larger field-of-view (FOV) 
(27); up to 48 B-scans per second can be taken and aligned to form a 3D image of the retina 
(see Figure 3.3) (57), with which the macular can be segmented to obtain a volume 
measurement in mm3. Macular volume scans present the opportunity to directly capture 
neuronal degeneration as 34% of the average macular thickness comprises the inner retinal 
complex (i.e. ganglion cell layer, inner plexiform and nuclear layers) (58). Decreases in 



























































































































































































Segmentation of OCT scans is commonly achieved automatically with proprietary software 
supplied by device manufacturers that separates the cell layers and gives thickness measures 
in micrometres. Peripapillary scans offer RNFL measurements taken at a radius of 3.4mm 
from the centre of the optic disk (as manually identified by the operator) (57). The thickness 
measures are then divided into 8 regions for analysis: global (G), superior temporal (TS), 
inferior temporal (TI), temporal (T), superior nasal (NS), inferior nasal (NI), nasal (N) and the 
papillomacular bundle (PMB). PMB is a measure created for the investigation of 
neurodegenerative diseases as it pertains specifically to information from the fovea- the region 













Figure 3.3: A visualisation of macular volume acquired using a Heidelberg 
Spectralis. On the upper surface we can see the blood vessels which emanate 
from the OD, whilst from the side there is shown one of the 48 B-scans which 
make up a 3D image of the macular.  
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To ensure multiple scans taken from the same patient at different timepoints can be compared 
longitudinally, OCT devices use registration techniques to align scans using the anatomical 
landmarks of the retina. The Heidelberg SPECTRALIS (Heidelberg Engineering, Heidelberg, 
Germany) simultaneously images the eye with 2 beams of light. One beam will map over 1000 
points of the eye in order to continuously track eye movement, whilst the other beam uses this 
mapping as a reference to image the retina regardless of blinks or movements from the 
participant (60). This registration technique allows for high degrees of repeatability not only 
between scans, but between each individual eye movement (intraclass correlation coefficient 
(ICC) = 0.99) (61).  
3.3 Scanning Laser Ophthalmoscopy  
 
 
The scanning laser ophthalmoscope (SLO) offers high-resolution images of the surface of the 
retina, using an infrared light source along with the principles of confocal microscopy (53). A 
laser (such as one with a wavelength of 820nm) is directed through the pupil illuminating a 
Figure 3.4: Schematic of the principles of SLO (53)  
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small region of the retina, approximately 10μm in diameter. Once a reflected signal has been 
detected and recorded, the beam is then moved to an adjacent position where another signal is 
measured. In this sense, each image is taken pixel by pixel in a raster pattern. Due to the 
confocal setup, only those signals which reflect from very close to the focal plane can be 
detected, which results in a higher imaging resolution (typically 5μm) than can be achieved 
with fundus camera systems (typically 7-10μm). 
With fundus photography, a poorly dilated pupil can represent a significant obstacle to good-
quality image capture (a problem exacerbated by the bright flash a patient experiences), but 
the use of infrared light alongside a confocal scanning protocol minimises the effect in SLO. 
Furthermore, infrared light penetrates deeper into the retina than the flash of light in fundus 
photography (53). This enables for useful information to be ascertained regarding the health 
of cell layers as deep as the RPE but it is not capable of quantifying the thickness of cell layers 
as OCT does. 
Scans are taken in as little as 24ms allowing SLO to be utilised for video capture. The FOV 
available in SLO varies, but rarely reaches above 60° (53). For this reason, it is mostly 
employed for imaging the central anatomical landmarks e.g., fovea and optic disk. However, 
the high-resolution images generated do present an opportunity to investigate the peripapillary 
blood vessels and any subsequent changes which may occur to them as a result of 
neurodegenerative disease.  
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3.3.1 Ultra-wide field imaging  
 
Typical fundus image capture is limited by the small FOV offered by standard fundus camera 
and SLO devices. While this is adequate to view the posterior pole containing the central 
anatomical landmarks, it is inefficient at imaging the peripheral retina, its vasculature and 
pathology. Multiple fundus images can be computationally stitched together in a mosaic to 
render an image with a larger FOV (see Figure 3.5), but transitions between images are 
sometimes broken or badly aligned making measurements of vascular features such as vessel 
width and tortuosity unreliable. Ultra-wide field SLO (UWF-SLO) combats this by capturing 
a single image with a much larger FOV in one go without the need for pupil dilation, specialist 
contact lenses or lens attachments. 
Figure 3.5: Stitching three fundus camera images together to create a larger FOV  
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Much like SLO, UWF-SLO images are created using a confocal, pixel-by-pixel approach. Two 
lasers are used for imaging: red (with a wavelength of 635nm) and green (with a wavelength 
of 532nm) (62). In tandem, both lasers are swept across an ellipsoidal mirror Figure 3.6 (63)). 
Whilst each laser is directed through one of the mirror’s focal points, the participant’s head is 
positioned against the device so that the second focal point lies on the participant’s retina. 
From here, the lasers move across the retina much like a conventional SLO.  
 
 
With just a 0.4s exposure time this technique enables capture of a pseudo-colour image (as 
there is no blue channel to create a true RGB image) whilst keeping patient discomfort at a 
minimum (62). With a maximum FOV of 200° (82% of the retina) UWF-SLO produces a 
Figure 3.6: Schematic of an Optos UWF scanner system (97). A) High speed rotating 
polygon mirror. B) A second, low speed mirror. C) Ellipsoidal mirror. D) Main 

















wealth of information on the retinal vasculature (63). However, artefacts such as eyelashes do 
limit coverage, and the superior/inferior regions of the retina may appear distorted in 
comparison to nasal/temporal regions. Although the resolution is less than with other types of 
fundus image (20μm vs. 7-20μm) and the participant experiences a bright flash of light, the 
FOV is much larger than that of SLO or fundus photography and scanning is not as affected 
by pupil contraction due to its confocal scanning mechanism (62). 
 
Due to the spherical shape of the eye, mapping of a 3D surface onto a 2D plane creates 
difficulties when preserving qualities such as distance, area and orientation. As the incident 
beam travels a shorter distance to reach the periphery of the retina, the absolute area these 
Figure 3.7: UWF-SLO image of the right eye once stereographically projected 
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pixels represent on a 2D image will be smaller than those pixels located closer to the fovea. 
As such, there is an ‘enlargement factor’ associated with a pixel’s angular location upon the 
retina (64). In imaging devices with small FOVs, the distortion has a negligible effect on 
measurements; it is only when considering large FOVs that this must be accounted for. Figure 
3.7 displays an image which has been stereographically projected to conserve angles, which 
in turn compromises measures such as area and distance (much as a map of the world distorts 
the sizes of countries whilst in turn conserving shape). If distance measurements are to be 
made, appropriate mathematical translations provided by the manufacturer (which set a default 
axial length of 24mm) must be accounted for in any calculations (65).  These calculations are 
based on theoretical formulations which have been tested and verified through the in vivo 
measurement of the Argus II retinal implant, the dimensions of which are precisely known 
prior to implantation (65).  
UWF-SLO has proved a useful tool when investigating diseases which manifest themselves in 
peripheral regions of the retina e.g., retinal vasculitis, retinal detachment and diabetic 
retinopathy, and as such has remained a tool largely focused on these conditions (63) (66). The 
application of segmentation algorithms which can create reliable maps of retinal blood vessels 
in UWF-SLO images could be used to quantify indicators of vascular health in the eye such 
as tortuosity, vessel widths and branching geometry, and as such see UWF-SLO utilised more 
commonly in a clinical setting (67). 
In contrast to OCT, fundus imaging has been under-utilised in biomarker discovery for 
neurodegenerative diseases. The lack of investigation is likely due to the sparsely available 
resources that allow for quantification of retinal features; unlike in OCT, SLO manufacturers 
do not provide segmentation software and as such, applications must be custom built. With 
the advent of novel computer algorithms to reliably segment the retinal vasculature in SLO 
and UWF-SLO images, it is now possible to investigate changes to the peripheral retinal 
vasculature in relation to neurodegenerative disease (68). 
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3.4 Visual acuity  
 
With visual symptoms, such as those associated with ON, being more common in patients with 
MS, visual function should be considered clinically when assessing a patient’s disability status. 
The leading outcome measure of visual disability in patients with MS is low-contrast visual 
acuity (LCVA), which attempts to quantify changes in retinal function through examining a 
patient’s ability to read from a Sloan letter chart (Figure 3.8) (41). 
Patients are required to sit approximately 3 metres from a backlit chart in a darkened room. 
One eye at a time, the patient identifies, from the top down, as many letters as possible from 
two charts; one full-contrast (100%) and another low-contrast (2.5%). As each chart 
progresses, the size of the letters decreases to not only test contrast sensitivity, but also measure 
a patient’s sensitivity to various spatial frequencies (41). Once completed, each eye is given a 
Figure 3.8: Low contrast letter acuity chart (LCLA) (41) 
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score based on how many letters (out of a potential 70) the patient correctly identified- this 
simple measure allows for linear statistical analysis but is still comparable to the logMAR 
system used by ophthalmologists when assessing ETDRS (Early Treatment Diabetic 
Retinopathy Study) - the current gold standard in research and clinical settings (41) (69). The 
test has an interrater reliability of 0.86 to 0.95 and is the most sensitive measure of visual 
dysfunction in MS currently available; a difference in score of 7 is considered clinically 
significant (41). 
Clinical studies pertaining to LCVA suggest the test acts as a measure of damage to the inter-
neural connections in the complex visual pathway and a recent review by Balcer et al. found 
that LCVA was a useful measure in determining impairment and disability from MS. LCVA 
has been found to correlate with EDSS, but also to decrease where EDSS score remains stable 
(41). This could suggest that LCVA may be able to discern changes to disability to which other 
measures are not sensitive (20). Axonal loss measured with OCT has also been found to 
correlate with a reduced LCVA score in both patients with and without clinical history of ON 
(42).  
3.5 Summary 
There are many modalities with which to capture images of the retinal anatomy, thus allowing 
investigation of the changes that may occur in patients with MS and other diseases. Much of 
the current research has relied on the ability of OCT to capture cross sectional images of the 
retina and subsequently measure thinning of the RNFL and a loss of ganglion cells. Such 
measures have been associated with brain atrophy and thus considered as a potential method 
of tracking disease progression (70). However, little research has been conducted on potential 
changes to the retinal vasculature, which may act as a useful surrogate for similar changes in 
the brain. With the advent of novel computer algorithms, which are tailor made to quantify 
vascular measures (e.g., vessel calibre, tortuosity etc.) in UWF-SLO images, comes the 
opportunity to investigate the vascular network in the retina of patients with MS, particularly 
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Chapter 4  
Materials and Methods  
4.1 Introduction  
This study was a preliminary investigation into possible changes which occur to the retinal 
blood vessels of patients with MS, and how these fit with known changes in RNFL thickness 
and macular volume. Multiple modalities of imaging were used to capture both the retinal cell 
layers and retinal vasculature, alongside visual acuity to quantify retinal function. This chapter 
will set out how the study addresses its hypotheses using a methodological, ethical and reliable 
approach to data collection and image analysis.  
4.2 Study design  
As investigating the peripheral retinal vasculature in patients with MS is a novel concept, there 
were no similar studies from which to estimate an effect size and perform subsequent power 
calculations. Importantly, this study aimed to provide just such data so that an estimate of the 
likely sample size needed for larger prospective studies could be calculated. Initial recruitment 
targets were therefore based on realistic expectations of how many individuals could be 
recruited from within the Anne Rowling Regenerative Neurology Clinic (ARRNC), Little 
France, Edinburgh, based on preceding MS studies run from within the clinic and their rates 
of recruitment. Thus, a target of 100 patients with MS, comprising 25 participants from each 
of the four MS subtypes, were to be enrolled with a further 100 age and sex matched HVs to 
act as a control group (recruited through word-of-mouth and staff emails sent to the local 
research community). Should a spouse or family member regularly accompany a participant 
with MS to their clinical consultations, they would also be approached to enrol in the study as 
a HV. 
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Competent and consenting patients with MS were recruited opportunistically; during a clinical 
consultation in the ARRNC with either a neurologist or MS specialist nurse the patient was 
approached regarding the opportunity to enrol in this study and given an information sheet to 
read. Potential participants were not approached directly by myself so as to not apply undue 
pressure to participate in the study or to breach patient confidentiality. Should the patient 
declare an interest in participating they were then introduced to me and I would answer any 
questions and detail the study more thoroughly. Patients were made aware that all identifying 
information would be removed from images prior to being exported from the ARRNC for 
analysis, and their participation in the study kept anonymous. It was also explained that they 
were free to withdraw from the study whenever they wished. All images would be reviewed 
by a clinical ophthalmologist for incidental findings and should any be found the patient would 
be contacted through their GP to take any necessary action. Exclusion criteria included any 
individuals who had undergone retinal surgery (other than laser vision correction), had severe 
myopia (i.e. -10 or more) or any pathologies which would compromise my ability to make 
accurate measurements with OCT or UWF-SLO images in at least one eye.  
If an eligible patient wished to commit to the study, written consent was obtained. The imaging 
protocol then started with OCT as it required the greatest amount of sustained concentration 
from a participant and scanning at the end of a session could risk patient fatigue and failure to 
complete. A decision was made in this study not to dilate pupils as this may reduce the number 
of participants willing to enrol, and a comparison of RNFL thickness measured in dilated and 
non-dilated eyes showed no significant difference with SD-OCT (71). VA tests were 
performed prior to UWF-SLO capture as this device emits a bright flash of light which may 
affect a participant’s performance in LCVA tests. Once baseline scans were acquired at this 
initial session, follow-up scans for participants with MS were taken alongside future clinical 
consultations so as to not inconvenience the participant with additional visits to the clinic. 
These would typically be every 3, 6 or 12 months. For HVs, follow up scans were arranged at 
approximately 6-month intervals at a convenient time for the participant. 
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All imaging was completed within the ARRNC between July 2015 and September 2017. Final 
recruitment numbers are shown in table 4.1. Only one of the healthy controls within this study 
was recruited as the spouse of an MS participant- this was mostly due to a lack of spousal 
company during clinical consultations. However, when approached to participate, healthy 
spouses were often rushed for time or put-off by the necessity to come in for follow-up scans. 
Information on participants with MS relating to their disease was identified by research nurses 
in the ARRNC using historic electronic patient correspondence. This included the initial date 
of MS diagnosis for each participant as well as any clinical history of ON, current disease-
modifying medication and the most recently available EDSS score. 
The length of disease ranged from 1.7 to 38.5 years. 46 MS patients were being treated with 
Characteristics Patients with MS 
(N = 72) 
Healthy Volunteers 
(N = 80) 
Median Age  44 38 
Age range 20-79 23-73 
Male 19 19 
Female 53 61 
History of ON (No. patients) 16 0 
History of ON (No. Eyes) 19 (OD  9, OS 10) 0 
Relapse-remitting  62 N/A 
Primary progressive 2 N/A 
Secondary progressive  7 N/A 
Disease-modifying therapies* 46  N/A 
 
Table 4.1: The demographic of people who took part in the study. ON = Optic Neuritis, 
OS = Left eye, OD = Right eye. *These include: Fingolimod, Tecfidera, 
Dimethylfumerate, Copaxone, Plegridy, Alemtuzimab and Tysabri. One MS 
participant’s disease subtype was unable to be determined from their electronic 
correspondence. 
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disease modifying therapies during the time of their participation in the study, 12 of which 
were prescribed Fingolimod (a drug associated with an increased risk of macular oedema) 
(15). Recent EDSS scores could only be found for 2 participants (scores of 0 and 7). Median 
age was slightly lower in the group of HVs when compared to participants with MS (38 and 
44 respectively), with the group of individuals with MS having a greater age range. An equal 
number of male participants were scanned in both the HV and MS groups, although more 
female HVs were scanned than females with MS. This was a consequence of the large number 
of responses from females (mostly young PhD students from the local research community) 
volunteering to be involved in the study. Of the MS participants, 8 right eyes and 10 left eyes 
had at least one previous episode of ON. 
Follow-up scans were successfully attained for 65 participants with MS and 72 HVs. The 
healthy controls for which follow-up scans were not attained had either moved away, making 
scanning unfeasible, or could no longer be contacted- most likely because they no longer 
worked/studied within the local research community. Follow-up scans for participants with 
MS were reliant on those individuals returning to the clinic for their scheduled clinical 
consultations, the dates and times of which were given to the research team in advance. In 
some circumstances, these individuals would miss their appointment or would simply opt for 
an over-the-phone consultation due to a lack of any progression in their symptoms. Patients 
were not contacted with respect to scheduling an extra clinic visit just for the purposes of 
having a follow-up scan for the study. 
The number of scans for each individual within the MS group ranged from 1 to 5, with the 
time difference between baseline and final scan ranging from 196 to 672 days. HVs were 
scanned between 1 and 3 times during their participation in the study, the time difference 




4.4 OCT imaging procedure 
OCT imaging was completed with a Heidelberg SPECTRALIS (Heidelberg Engineering, 
Heidelberg, Germany). Prior to scanning, participants were given a brief introduction to what 
the OCT device does and how it works as well as simple instructions to be followed during 
the scan such as where to direct their gaze. Effort was made to ensure each participant was 
comfortable resting their head in the correct position by adjusting the height of the apparatus. 
A small internal blue light was used to help fixate the participant’s gaze in the desired position 
for a given scan. Should a participant have trouble fixating on the dot (either because they 
were partially sighted or fatigued by the scanning), external red LED antennas were used to 
help direct a participant’s gaze to the correct orientation. Participants were free to blink during 
the scanning and if at any point they felt uncomfortable, a short break and adjustment of the 
apparatus was offered. In chronological order, the scans taken were as follows: 
• Horizontal line scan- a straight line which runs from the centre of the optic disk, 
through the foveal dip. Automatic real time (ART), which is a measure of how many 
scans are averaged to compile a single image with the SPECTRALIS, was set at 100 
as per the manufacturer’s recommended acquisition protocol. Scans are averaged 
using the registration techniques laid out in the previous chapter.  
• Vertical line scan- a line which runs perpendicular to the horizontal line scan, once 
again passing through the foveal dip. ART set at 100 as per the manufacturer’s 
recommendation.  
• Posterior pole scan- a volume scan which allows for measures of macular volume, 
comprising multiple line scans perpendicularly aligned across the macula. ART for 
each individual line scan was set at 12, as per the manufacturer’s protocol. 
• Peripapillary scan- a line scan which is taken in a circular fashion around the optic 
disk, with a radius of 3.4mm. ART set at 100. This was taken last as it was the only 
scan requiring the participant to fixate on the light appearing at the side of their vision 
towards their nose, so as to centre the image on the optic disk rather than the fovea. 
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In volume scans the ART was set lower than in 2D scans as the increase in SNR that comes 
with higher ART would not compensate for the large amount of time it would take to complete 
the acquisition; patients with MS would often begin to feel fatigued during the scanning 
process and struggle to remain fixated for long time periods. Moreover, segmenting the 
macular in volume scans is often simpler than segmenting single cell layers such as the RNFL, 
as the boundaries are much better defined. This in turn allows for a smaller SNR for the 
acquired image. For each scan, a participant would have multiple images taken for each eye; 
the best scan was selected through careful assessment of three areas: 
• Quality score- this is a measure of signal strength given by the manufacturer’s 
propriety software. Scans with a score less than 25 were deemed too poor to gather 
accurate and precise thickness values of individual cell layers. It has been shown that 
signal strength in SPECTRALIS OCT scans are negatively associated with RNFL 
thickness measures (poor quality scans overestimate thickness values) (72). 
• ART score– though with line scans the ART was set at 100, this was not always 
attainable if the patient was restless, blinked frequently or had mild cataracts. This 
was due to the real-time tracking algorithm employed by the SPECTRALIS described 
in the previous chapter. As such, the scan which had the largest ART score generally 
had the greatest definition between cell layers and was selected for analysis (see 
Figure 4.1) (73). Studies have shown that an increased ART score is associated with 
better reproducibility and reduced short term and day-to-day variability in RNFL 
thickness measures made using the SPECTRALIS device (74).  
• Quality of segmentation- largely, the quality of the segmentation was dependent on 
the signal strength and ART score. However, on some occasions, artefacts or 
misaligned scans would cause erroneous segmentation by the software (see Figure 
4.5). If so, the image with the most accurate segmentation of cell layers (or macular 




























































































































































































































































A degree of post-processing was required with the OCT scans. The accuracy of regional 
peripapillary RNFL thickness measurements are dependent on correct identification of the 
fovea (as regions are created using fovea and optic disk position). Though foveal segmentation 
is automated, it was checked by the operator and adjusted if necessary. An example of correct 
foveal segmentation is shown in Figure 4.3 with a blue line which connects the centre of the 
optic disk to the centre of the fovea. Also shown in Figure 4.3 are the RNFL thickness 
measures in µm for each region produced by the device’s own analysis software (HEYEX, 
software version 6.5, Heidelberg Engineering, Heidelberg, Germany). It was equally important 
that the fovea was correctly identified for macular volume scans (see Figure 4.4). Once again 
this is a semi-automated process, with manual fine-tuning of the position essential. Foveal 
position was deemed correct when the pixel directly in the centre of the measurable area was 
located at the place of minimal retinal thickness (in line with the foveal dip). 
To eliminate any errors in segmentation, the operator would assess the quality of segmentation 
visually in all scans. To minimise human error, the segmentation (if seen as inaccurate) would 
be run automatically a second time with the device’s software; the robust image analysis 
algorithms used to segment the scans had a high rate of reproducibility (ICC = 0.988 for mean 
RNFL thickness) making it favourable over manual segmentation (75). Should the results still 
be considered erroneous, minimal manual corrections were made by the operator to correct the 
segmented area to one which was deemed more accurate by visual inspection (see Figure 4.5). 
Small segmentation errors were common around the retina’s surface blood vessels as the 
lumens of these vessels lay within the RNFL, and the subsequent reflection of incident infrared 
light causes vertical shadows down to the choroid, disrupting segmentation slightly. Unless 
this caused any egregious errors (10 pixels or more), they were left uncorrected as it would 
take a considerable amount of time for the operator to correct all of them and would thus be 
impractical. Errors which required manual correction were rare and often due to subtle 
artefacts or poor scan quality, but nevertheless had to be manually refined to improve accuracy 
(76). Secondly, intervention by the operator was kept to a minimum as automatic segmentation  
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around blood vessels in a follow-up scan were likely to be comparable to segmentation in 
baseline scans, therefore being a more consistent approach than manually correcting 
segmentations when investigating longitudinal changes in the data (75). 
Once a baseline scan is taken for a person, it is set as a reference for all of their future scans; 
whenever a participant has a new scan, the SLO image of the fundus is automatically registered 
to the baseline image so that the new OCT scan is acquired in the same location and orientation 
as the original. All previously manual interventions such as fovea-placements are then 
automatically aligned with the original scan allowing for a direct longitudinal comparison. 
Reproducibility and repeatability measures of mean retinal thickness are reported by the 
manufacturer with standard deviations of 1.6µm and 1.1µm respectively (57). Outliers, i.e. 
suspiciously thick or thin measurements, were identified using box plots for each of the three 
participant groups: HVs, participants with MS but no clinical history of optic neuritis i.e. MS 











4.5 UWF SLO imaging procedure 
UWF-SLO scans were acquired using an Optos Daytona (Optos, Dunfermline, Scotland). 
Participants were given brief instructions specific to this imaging procedure and made aware 
of the bright flash they would experience when the image is taken. To acquire the best possible 
images, participants were asked to keep both eyes open regardless of which eye was being 
scanned. If participants struggled to assume the correct head position for scanning, I would 
intervene and with their permission gently guide the participant’s head accordingly. 
Participants had two images of each eye taken and the best image from each eye was selected 
for analysis. Image quality was determined by how clearly both the optic disk and fovea could 
be viewed and the amount of peripheral vasculature that was visible. Images were exported in 
non-compressed TIFF format (to preserve detail) and sent for stereographic projection which 
re-maps the image to account for the curvature at the back of the eye, conserving angular 
dimensions about the fovea.  Projected images were then assessed for quality of the projection; 
a file containing the “Maximum percent error in area measurement” which was automatically 
created for each image was made available by Optos. Should this value be above 1, the image 
was declared poorly projected, upon which manual identification of the fovea was made. The 
coordinates of the fovea were then used to re-project the image with the aim of producing a 
better projection with an error of <1. If the error remained above the threshold of 1, then the 
image was discarded as converting pixel measurements made of the vasculature into mm 
measurements relies on the accurate re-mapping of the retinal image (65). If an image was 
successfully projected, it was then prepared for analysis by segmenting the retinal vasculature.  
To enable the best possible segmentation of the retinal vasculature, a mask was created 
manually to crop out features such as eyelashes and the eyelid that would interfere with this 
process and lead to artefacts. Though this reduces the usable FOV of the image, the resulting 
region of interest (ROI) will still be considerably larger than that of a conventional fundus 
camera or SLO. The masks were designed to maximise the amount of visible peripheral 
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vasculature, whilst mitigating against artefacts. Some artefacts (mostly eyelash) were still 
included in the useable ROI if excluding them meant also excluding a large percentage of the 
retinal vasculature. Then the image is segmented to produce a binary map of the blood vessels 
detectable on the surface of the retina (Figure 4.6) (68).  
While this map will subsequently be used for quantifying vessel widths, it is not a perfect 
representation of the vascular network; accuracy of the algorithm has been reported as 0.965 
± 0.006 (68). Some smaller vessels fail to be segmented due to the lower resolutions inherent 
to UWF-SLO imaging, and the vessel network itself may contain inaccuracies at complicated 
junctions or vessel crossings. Therefore, a skeletonised version of the binary map (with vessels 
represented with only a 1-pixel diameter) was created whereby vessels are connected within a 
graph structure by individual ‘nodes’, which either represent the start/end of a vessel, a vessel 
crossing or a junction at which a vessel bifurcates. Next, each image’s skeleton was subjected 












































































The purpose of the manual correction step was to create as accurate a representation of the 
vascular network as was possible whilst minimising the likelihood of erroneous vessel 
measurements. This first meant the deletion of false positives which were actually 
representations of something other than the retinal vasculature e.g., eyelashes, drusen, 
choroidal vessels. In Figure 4.7, the effects of a blonde fundus are shown, whereby choroidal 
vessels are observable through the retina and are subsequently segmented unintentionally due 
to their similar appearance to retinal vessels e.g. their width and piecewise linear structure. For 
measurements of retinal vessels to be accurately quantified, it was important to remove false 
positives from the vessel skeleton. 
 Segments were also corrected manually when two vessels that lied parallel to one another 
were represented as a single vessel rather than two distinct structures, which would prevent 
accurate width measurements (Figure 4.8). Similarly, it was common for vessels close to the 
optic disk to run parallel to one another without a distinguishable gap between them, meaning 
when it came to measure the width of these vessels, the resulting analysis would be incorrect. 
In this scenario, both vessel segments were deleted until the separate vessel paths could be 
resolved.  
In some circumstances, a small portion of a vessel would fail to be segmented. Though this 
may seem insignificant, when vessel paths are later identified (stretching from the optic disk 
to the outer periphery) such scenarios would lead to two distinct and separate structures rather 
than one complete vessel tree, essentially splitting a vessel path in half (Figure 4.9). As the 
main advantage of UWF SLO imaging is its ability to view the peripheral retina to give 
measurements of long vessel paths, this inaccuracy was corrected wherever possible. On small 
scales vessels are piecewise linear, so such corrections are merely straight-line paths. 
However, if the distance between the two segmented pieces of vessel is too large, joining the 
two segments with a straight line may not be representative of the true path taken by the vessel. 












































































































































































































































































small enough that a straight line could be considered a viable representation of the vessel’s 
true path. 
Vessel segments that were falsely connected were separated at a crossing or junction by 
creating a new node- what was once a single vessel will be two vessel segments that connect 
to a newly created node (Figure 4.10). Having corrected the skeletonised vessel map, myself 
as the operator then manually identified segments as being either arteries or veins to create 
separate arterial and venular trees. These are essentially networks, whereby each vessel can be 
traced from its original parent segment (next to the optic disk) to its end node in the periphery 
of the retina.  
Distinguishing between the two vessel types can sometimes be speculative and open to 
interpretation, however by using the following rules an accurate classification can mostly be 
achieved by a trained observer. 
• A crossing of two vessels will never consist of two vessels of the same type i.e. 
one will always be a vein and the other an artery.  
• Veins appear thicker and darker than arteries due to transporting deoxygenated 
blood. 
• Veins and arteries generally alternate when emanating from the optic disk. 
Finally, the processed images were used to identify which vessels to use for biomarker 
analysis. Due to the longitudinal nature of the dataset, it was important to ensure the same 
vessels were being analysed consistently for each participant’s follow-up scans, regardless of 
difference in image quality, orientation or length of vessel path. Each image was split into four 
quadrants: nasal inferior, nasal superior, temporal inferior and temporal superior. Quadrants 
















































centre of the fovea for superior/inferior hemispheres and another line perpendicular to this for 
the nasal and temporal regions. For each image, a maximum of 8 vessels were selected- 4 veins 
and 4 arteries. Vessels were selected such that each artery/vein originated from within one 
quadrant of the retina. If there were multiple vessels to choose from within a given quadrant, 
the vessel path selected would be the one which had the longest path regardless of which 
quadrant the vessel path ended in. If there was a choice between two vessels of approximately 
equal path length, the vessel which ended closest to the centre of the quadrant in which it began 
was selected. The same vessel was selected for each follow-up image, therefore if a vessel had 
Figure 4.11: Example of the 8 vessels selected for analysis in a participant. Veins are 
coloured blue and arteries red, with the nodes (i.e. crossings, bifurcations, start and end 
points) plotted as green crosses. 
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a large path length but was obstructed within one of the follow-up images of the same 
participant, a shorter vessel which appeared in every image was instead selected.  
As vessel widths decrease as a function of their path length (from the optic disk to the 
periphery), care was taken to create a standardised vessel width measure from within a specific 
location on the retina. To enable direct comparison between participants, only select portions 
of each of the 8 main vessels were used when measuring vessel calibre. Any pixel from a 
selected vessel which lay between 6.5 and 8.5 optic disk radii away from the optic disk centre 
was used for vessel width analysis (see Figure 4.12). Prior to width measurements being taken 
a spline refinement algorithm was incorporated to smooth the edges of the vessels (77) (68). 
Estimates of the true vessel width were then calculated using gaussian-fit adaptations and an 
algorithm by Lupascu et al. which utilises cross-sectional intensities of the vessels alongside 
bagged decision trees (78). Width measures were taken from each quadrant separately so as to 
determine any anatomical changes specific to particular regions of the retina (as shown in 
RNFL data). Further to this, measurements taken from participants with a history of ON were 
separated for each eye so as to investigate the potential changes to retinal blood vessels caused 
by oedema during ON. All vessel width measures were converted from pixel to millimetres 
using an algorithm supplied by Optos that accounts for a pixel’s global position on the retina 
with respect to the fovea (79). 
Graphical representations of the raw data produced from this targeted approach, such as those 
shown in Graph 4.1, highlighted a clear positive skew in vascular width measurements for all 
four quadrants. Width measures which were found to be beyond the 95% confidence interval 
for each quadrant were therefore investigated manually and the majority of these were 
discovered to be representative of erroneous segmentations around vessel crossings or 
bifurcations, which in turn caused a larger width measure than was deemed accurate by visual 
inspection. Such points were removed from the UWF-SLO dataset and the remaining width 











Figure 4.12: A visual representation of the region from which vessel widths are 
measured in UWF-SLO data; the area between the rings lies between 6.5 and 
8.5 OD diameters from the OD centre. Green lines mark the boundaries of each 
quadrant, created from a line which bisects to centre of the OD and the centre 





















Graph 4.1: Normal probability plot for vessel width measurements in 
the left eye (OS) showing a positive skew in both arteries and veins 
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4.6 Visual acuity procedure  
Visual acuity was measured for each participant whenever possible. If a participant was 
without spectacles worn for myopia, then the test was abandoned. Whilst sat 3 metres away 
from a backlit 100% Sloan letter chart, participants were first asked to read the characters, 
from the top, one eye at a time. For consistency, the eye not being tested was covered with an 
opaque object. Participants would continue to the following line providing they identified 3/5 
letters correctly. Scores were tallied before changing the chart to one which measured 2.5% 
LCVA. From here, the process was repeated with instructions for the participant to take their 
time, and not to worry if letters came in and out of focus. During the process, lights in the 
room were switched off to allow for the greatest contrast between characters on the charts. As 
visual acuity data was collected manually at the time of each participant’s visit to the ARRNC, 
no data was excluded for use in analysis upon inspection of outliers.  
4.7 Statistical methods  
The data were analysed statistically using MatLab and the Statistics Toolbox (Release 2015a, 
The MathWorks, Inc., Natick, Massachusetts, United States). Normality of the data collected 
was tested using a selection of objective and subjective approaches. For participant groups 
with a sample size N>50 (e.g., HV, MS (no ON)) a Lilliefors test was utilised, which rejects 
the null hypothesis that data is normally distributed at the 5% significance level. Due to the 
low number of participants generally (N<100) in each group, the p-values produced were not 
deemed enough to be used definitively as a test for normality. Therefore, the data were also 
visually assessed using box plots to look at symmetry and histograms to identify Gaussian 
distribution curves, while normal probability plots aided in uncovering any inherent 
skews/lack of normality. In circumstances where N<10, such as in the MS (ON) group, data 
points were too few to reliably assess normality and were treated as being non-normal during 
statistical analysis.  
Where data was found to be normally distributed, a two-sample t-test was used separately for 
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each eye to identify significant differences between the retinal parameters measured from each 
participant group: HV, MS (no ON) and MS (ON). For sample distributions where N>30, 
confidence intervals for differences in the mean where calculated using the central limit 
theorem: the standard deviation of a sample distribution is approximately equal to that of the 
sampling distribution’s (80). In cases where N<30 e.g. MS (ON), confidence intervals were 
estimated: a t-distribution represented the shape of the sampling distribution, under the 
assumption that the group distribution was normally distributed. In non-normal datasets, 
differences in the median value were instead investigated using the Wilcoxon rank sum test, 
as this does not rely on the assumption of a Gaussian distribution within the datasets being 
compared. 95% confidence intervals (CIs) were calculated using a bootstrap function, which 
creates a distribution of the difference in medians between 1000 resampled groups and ranks 
these values from lowest to highest and provided an estimate of the 95% CIs of the actual 
dataset. 
To determine the effects of potentially confounding variables in the retinal parameters 
measured, the data was analysed using multivariate linear regression models in 
correspondence with similar studies of OCT data (33) (42) (35). Despite a tendency in the 
literature to adjust for intraocular variations within regression models, or to assume left and 
right eyes to have a high degree of intercorrelation, this study kept eye data separate so as to 
investigate lateral asymmetry, which has been found in RNFL thickness measures of healthy 
individuals (81). Due to the low sample size of participants with a clinical history of ON (OD: 
N = 9, OS: N = 10), only MS participants without a clinical history of ON were included in 
this analysis.  As per regression models put forward by comparable studies, age was 
considered as one of the possible predictors along with two binomial variables: disease 
(disease vs no disease) and sex (female vs male) (27) (82).  
To determine the combination of predictors which produced the models which most accurately 
described the data whilst avoiding overfitting, the model which was both significant and 
explained the greatest variation in the data (i.e. had the largest adjusted R-squared value) was 
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identified. Should no model be significant, then selection was based on the adjusted R-squared 
value alone. The coefficients produced by the selected models were then used to assess the 
effect that each predictor has on the measured anatomical changes in the retina, along with 
their significance. In order to assess the robustness of each model, they were verified 
subjectively; the residuals from a model were tested for normality (to ensure a linear model is 
correct for characterising the data) via box plots, histograms and normal probability plots, and 
the model was run again once the most influential data points had been removed. Influential 
points were identified as those having a Cook’s distance which was greater than 3 times the 
mean Cook’s distance for the dataset from which it came (83). Remodelling once these points 
had been removed allowed an understanding of whether a model was robust or susceptible to 
a large degree of change towards a few highly influential pieces of data. 
MS (no ON) data was isolated to investigate the potential of length of disease (from date of 
diagnosis to date of baseline scan) to act as a predictor of retinal anatomical measures.  Age 
and sex were again considered as possible predictors when constructing these models. For 
macular volume, an additional predictor, fingolimod, which identifies individuals who are 
being treated with Fingolimod during their enrolment within the study, was also included as a 
possible predictor, as taking this drug has been associated with an increased macular volume 
(84) (85).  
Though the intervals between follow-up scans were approximately 3, 6 or 12 months apart, 
for use in statistical analysis the intervals were too irregular for a direct comparison of changes 
in the retinal anatomy between different participants. As such, any changes seen in the 
anatomy of each participant were standardised as a rate-of-change per year, a technique 
mirroring that of another study found in the literature which imaged participants longitudinally 
at irregular intervals (35). This approach allows for participant-to-participant comparison 
regardless of the time elapsed between baseline and follow-up scans. For each individual who 
had received at least one follow up scan, a first order polynomial was fitted to their follow-up 
data, and the gradient of this line was used for calculating rate-of-change per year. Despite 
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some participants receiving scans over a period of time which is greater than two years, any 
changes which occurred in the retina over this period of time (rather than over the entire 
disease course) were predetermined to be piece-wise linear in their nature, hence the use of a 
first order polynomial. This is not to say that the pattern of change over an entire lifetime 
would necessarily fit a linear model, but it was deemed an appropriate approximation for this 
study. All follow-up scans for each participant (not just the baseline and final follow-up scan) 
were used to fit the polynomial so as to gain the most accurate measure of rate-of-change and 
to reduce the potential bias of observational errors. Outliers in the calculation of rate-of-change 
were investigated to ensure their validity when included in the dataset, or removal if found to 
be erroneous. 
This method was also applied to visual acuity data; the annual drop in score from Sloan letter 
charts were calculated using a first order polynomial with all follow-up data from each 
participant. What constitutes a clinically significant change in visual acuity has previously 
been investigated and argued in the literature. The test/re-test differences in someone with 
stable visual functionality can be substantial, and as such only seemingly large changes are 
seen as significant. Some studies suggest a 2-line (10 letter) difference to be beyond the reach 
of test-retest variability, thus constituting a measurable change in visual functionality (86). 
However, a recent study similar to this one suggests that a drop of 5 letters in HCVA and 7 
letters in LCVA is unlikely to be due to testing error and as such this criterion was adopted 
here (42).   
Due to the very nature of follow-up scans, age and length of disease varies as a function of 
time from baseline to final study visit (by more than 2 years for some participants). Although 
this would be normalized throughout the participant groups if all follow-up scans were taken 
at the same time intervals, due to the irregular scanning visits previously mentioned, the 
amount of variation in age and length of disease for each participant is dependent on the length 
of time between scans. As such, age used for follow-up regression analysis was the age of the 
participant at exactly half way between their baseline and final scan, and likewise for length 
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of disease. This helped to standardise time-dependent variables so as to have a more accurate 
representation of their effects on the rate-of-change in the retinal anatomy, should they be 
found to have an effect.   
4.8 Summary 
This is the first study to investigate the retina’s peripheral vasculature and the potential effects 
of MS on its health. Analysis of UWF-SLO images was made possible through the use of 
semi-automated algorithms which produce reliable measures of arterial and venous width. The 
study was planned to address its hypotheses in a reliable and methodological manner, having 
recruited HVs and patients with MS who underwent identical scanning procedures at multiple 
time points, to collect baseline and longitudinal data on anatomical changes to the retina. Care 
was taken to ensure the scans were both taken and analysed following a strict protocol which 
would allow for direct group and participant comparisons. Alongside UWF-SLO imaging, 
OCT scans and visual acuity scores were recorded during a participant’s visit so as to 
investigate reproducibility of the results of previous studies on the effect of MS on the retina’s 
anatomy and functionality. With consent, patient records were used to identify clinical data 
such as date of diagnosis and clinical history of ON, to be used in regression analysis at 




Chapter 5  
Baseline Data Analysis 
5.1 Introduction 
This chapter details the analysis of baseline data by the methods described in chapter 4; 
analysis was aimed at addressing hypotheses 1 and 2 as outlined in chapter 1. Namely, whether 
macular volume, RNFL thickness and vessel width were statistically significantly different 
when comparing certain retinal regions from each of the three participant groups.  Linear 
regression models are used to highlight any anatomical changes associated with disease 
without the potentially confounding factors of age and sex.  
5.2 Data cleaning  
Due to an excess of HVs, the youngest 8 females from within the control group were excluded 
from analysis. This reduced the difference in the median age of the two group demographics 
by 2 years and created an identical ratio of female:male HVs as that of the MS group.  
Exclusion of this data was purely on the basis of age and sex; table 5.1 shows the final 
demographics used for baseline analysis. For a small number of participants, a good-quality 
OCT image capture was not successful with the Heidelberg SPECTRALIS: one healthy 
control suffered from age-related macular degeneration and some individuals with MS were 
not able to sustain focus for the entire scanning procedure. Manual inspection of outliers 
resulted in one individual’s baseline data being excluded from the study as they were suffering 
from ON at the time of the scan and the resulting oedema was causing a swelling of the retina. 
As such, this individual’s first follow-up scan (once the symptoms of oedema had subsided) 





The final number of usable OCT scans are shown in table 5.2. Likewise, as the UWF-SLO has 
a fixed focal point the imaging procedure was sensitive to patient movement meaning not all 
images were of a good enough quality to analyse. Even when an image captured is of a suitable 
quality once projected, with both the OD and the fovea visible, a portion of the image may still 
be obstructed by eyelashes or eyelids that prevents analysis of the retinal vessels. Tables 5.3 
and 5.4 display the number of UWF-SLO images for both MS and HV groups that have vessels 
present in each of the quadrants, which were then able to be segmented and used for analysis. 
Characteristics Patients with MS 
(N = 72) 
Healthy Volunteers 
(N = 72) 
Median Age  44 41 
Age range 20-79 24-73 
Male 19 19 
Female 53 53 
History of ON (No. patients) 16 0 
History of ON (No. Eyes) 19 (OD 9, OS 10) 0 
Relapse-remitting  62 N/A 
Primary progressive 2 N/A 
Secondary progressive  7 N/A 
Disease-modifying therapies* 46 N/A 
 Multiple Sclerosis Optic Neuritis  Healthy volunteers  
 OS OD OS OD OS OD 
Baseline scans of 
usable quality  60 59 10 8 72 71 
Table 5.1: Adjusted group demographics for analysis. ON = Optic Neuritis, OS = left eye, 
OD = right eye. *These include: Fingolimod, Tecfidera, Dimethylfumerate, Copaxone, 
Plegridy, Alemtuzimab and Tysabri. One MS participant’s disease subtype was unable to 
be determined from their electronic correspondence. 
Table 5.2: Number of OCT baseline images for each participant group which were of good 










Number of images from which arterial data could be taken for each individual 
quadrant  
 Healthy Volunteers MS (no ON) MS (ON) 
Region OS OD OS OD OS OD 
Temporal 
Inferior  64 57 54 53 9 5 
Temporal 
Superior 68 70 56 61 10 8 
Nasal 
Inferior 55 58 35 46 7 4 
Nasal 
Superior 68 70 54 58 9 8 
 
Number of images from which venous data could be taken for each individual 
quadrant  
 Healthy Volunteers MS (no ON) MS (ON) 
Region OS OD OS OD OS OD 
Temporal 
Inferior 65 62 54 55 9 8 
Temporal 
Superior 66 70 58 61 10 8 
Nasal 
Inferior 57 64 37 50 8 7 
Nasal 
Superior 69 72 55 59 10 8 
Table 5.4: The number of images for each group from which venous data could be taken, 
from each of the four quadrants  
 
Table 5.3: The number of images for each group from which arterial data could be taken, 
from each of the four quadrants  
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5.3 OCT analysis 
Data for HV and MS (no ON) groups were judged to be normally distributed in both eyes. 
Mean RNFL thickness was found to be thinner in the MS (no ON) group than in HVs (see 
Table 5.5), with a significant mean global reduction measured in both eyes at baseline (left 
eye (OS): -10µm, p<0.001; right eye (OD): -11µm, p<0.001), corresponding to a 10% and 
11% drop in the left eye and right eyes respectively (see Table 5.7) . The largest reduction 
within my dataset was observed by an unpaired samples Student’s t-test in the inferior 
temporal regions and was 15µm (p<0.001) in left eyes and 13µm (p<0.01) in right eyes. 
Significant differences were likewise observed in the temporal region (OS: -11µm, p<0.001; 
OD: -12µm, p<0.001) and the superior temporal region (OS: -10µm, p<0.01; OD: -9µm, 
p<0.05) of both sets of eyes. The temporal region (OS: -16%, OD: -17%) of the MS (no ON) 
group saw a greater difference in RNFL thickness as a percentage of the HV’s RNFL thickness 
than all over regions in both eyes, including the temporal inferior region (OS: -10%, OD: -
9%). Nasally the mean RNFL thickness in the MS (no ON) group was reduced when compared 
to HVs at baseline, although these differences were less pronounced, with only the superior 
nasal (OS: -9µm, p<0.05; OD: -9µm, p<0.05) and nasal (OS: -8µm, p<0.01; OD: -11µm, 
p<0.001) regions showing a significant difference. A significant reduction in macular volume 
was also observed in MS patients (OS: -0.22mm3, p<0.01; OD: -0.3mm3, p<0.001) when 
compared to HVs, corresponding to a 3% and 4% drop in volume for left and right eyes. 95% 
CI’s were negative (showing a decrease in thickness or volume) for all regions within the MS 
(no ON) group except the inferior nasal region in both sets of eyes.  
A reduction of the RNFL was observed by Mann-Whitney U test to be greatest in eyes which 
had a clinical history of ON (see Table 5.6). Once again, the temporal regions played host to 
the largest reduction when compared to HVs, with the greatest difference in the temporal 
region of the left eye (-30.5µm, p<0.001), and the superior temporal region of the right eye (-
23µm, p<0.05).  Although the temporal region of the left eye measured the greatest difference 
 67 
in terms of percentage (-43%) of median HV RNFL thickness, it was the superior nasal region 
which showed the greatest percentage difference (-22%) in the right eye. Differences between 
the HV and MS (ON) groups were significant in all circumstances but the inferior temporal 
region of the right eye. When compared to participants with MS (no ON), the reduction was 
only found to be significant via Mann-Whitney U test in the temporal region of the left eye (p-
value < 0.05). Greater anatomical changes associated with ON were also reflected in macular 
volume, where the loss of volume when compared to HVs was found to be significant in both 
eyes (OS: -0.64mm3, p<0.001; OD: -0.52mm3, p<0.05), corresponding to a 7% and 6% lower 
macular volume in the left and right eye respectively. Once more, although a greater loss of 
macular volume was seen in the MS (ON) group than in the MS (no ON) group, the difference 













Mean RNFL thickness          
(µm ± SE) 
The difference from mean HV baseline RNFL thickness 
in µm (95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 
Region OS OD OS OD OS OD 
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Mean macular volume 
(m𝑚# ± SE) 
The difference in from mean HV baseline macular volume in 𝑚𝑚# 
(95% CI) 
Healthy Volunteers  MS (no ON) MS (ON) 
OS OD OS OD OS OD 







* p <0.05, ** p <0.01, *** p <0.001 
Table 5.5: The difference in mean baseline RNFL thickness for MS participants when 
compared to the baseline RNFL thickness of HVs using an unpaired samples Student’s t-
test, in each peripapillary region, as well as for macular volume. SE = standard error. CI 







 Median RNFL 
thickness in µm (IQR) 
The difference from median HV baseline RNFL thickness in 
µm (95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 
Region OS OD OS OD OS OD 































































































volume in m𝑚# (IQR) 
The difference from median HV baseline macular volume (𝑚𝑚#)  
Healthy Volunteers MS (no ON) MS (ON) 













* p <0.05, ** p <0.01, *** p <0.001 
Table 5.6: The difference in median baseline RNFL thickness for MS participants when 
compared to the baseline RNFL thickness of HVs using the Mann-Whitney U test, in each 
peripapillary region, as well as the difference in macular volume. IQR = interquartile 




















% change between mean HV baseline RNFL thickness and the 
MS (no ON) group  
 OS OD 
Global -10 -11 
Temporal -16 -17 
Temporal Inferior -10 -9 
Temporal Superior -7 -7 
Nasal -11 -14 
Nasal Inferior -5 -7 
Nasal Superior -8 -9 
% change between median HV baseline RNFL thickness and the 
MS (ON) group  
 OS OD 
Global -24 -16 
Temporal -43 -21 
Temporal Inferior -19 -15 
Temporal Superior -19 -17 
Nasal -21 -20 
Nasal Inferior -17 -20 
Nasal Superior -16 -22 
Table 5.7: The percentage change between the mean and median RNFL thickness of 







5.4 UWF-SLO analysis 
UWF-SLO vessel width data for HV and MS (no ON) groups was judged to be normally 
distributed. The full results for each participant group’s mean vessel thickness for both arteries 
and veins is displayed in Table 5.8.  In both eyes, the mean arterial width for MS (no ON) was 
significantly reduced when compared to HVs (OS: -7%, OD: -10%) when using an unpaired 
samples Student’s t-test in the inferior nasal quadrant (OS: -0.005mm, p<0.05; OD: -0.007mm, 
p<0.05): this also being the quadrant which showed the greatest differences in mean arterial 
width between HV and MS (ON) groups and the only region for which 95% CIs were both 
negative. In all other regions the differences measured lacked statistical significance, and in 
no region was the percentage change greater than in the inferior nasal region (see Table 5.10). 
Differences between the MS (no ON) and HV groups in the mean width of retinal veins were 
likewise found to be greatest in the inferior nasal quadrant (OS: -6%, OD: -6%)) in both 
absolute and percentage difference, although only in the right eye was the difference found to 
be significant (OS: -0.005mm, p=0.06; OD: -0.005mm, p<0.05). Left eye data measured a 
reduction in the mean thickness of retinal veins in every quadrant, however right eye data 
measured reductions in only the nasal quadrants, with no change in the superior temporal 
quadrant and a small increase in thickness for the MS (no ON) group in the inferior temporal 
quadrant.  In no region were 95% CIs both negative, although in three regions (including the 
inferior nasal) the upper interval was estimated at zero. No significant differences were found 
in either eye between HVs and MS (ON) participants when comparing median arterial or 
venous width, as shown in Table 5.9. The pattern of reduced vessel width in participants with 
MS was not seen in the MS (ON) group, with only half of the tested quadrants showing a 
reduction in median vessel width- the other quadrants either showing an increase in thickness 







(mm ± SE) 
The difference from mean HV baseline arterial thickness in 
mm (95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 











































































Mean vein thickness  
 (mm ± SE) 
The difference from mean HV baseline vein thickness in mm 
(95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 









































































*p <0.05, **p <0.01, ***p <0.001 
Table 5.8: The difference in mean baseline vessel thickness for MS participants when 
compared to the baseline vessel thickness of HVs using an unpaired samples Student’s t-
test, in four quadrants. SE = standard error, CI = confidence interval, OS = left eye, OD = 









thickness in mm 
(IQR) 
The difference from median HV baseline arterial thickness in 
mm (95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 













































































thickness in mm 
(IQR) 
The difference from median HV baseline vein thickness in mm 
(95% CI) 
 Healthy Volunteers MS (no ON) MS (ON) 









































































* p <0.05, ** p <0.01, *** p <0.001 
Table 5.9: The difference in median baseline vessel thickness for MS participants when 
compared to the baseline vessel thickness of HVs using a Mann-Whitney U test, in four 
quadrants. IQR = interquartile range, CI = confidence interval, OS = left eye, OD = right 


























Vessel type % change between mean HV baseline vessel 
thickness and the MS (no ON) group  
 OS OD 
Arteries Temporal inferior  -3 -5 
Temporal superior  -3 -2 
Nasal Inferior -7 -10 
Nasal Superior -1 -4 
Veins Temporal inferior  -4 1 
Temporal superior  -2 0 
Nasal Inferior -6 -6 
Nasal Superior -3 -4 
Vessel type % change between median HV baseline vessel 
thickness and the MS (ON) group  
 OS OD 
Arteries Temporal inferior  -4 -5 
Temporal superior  +1 +4 
Nasal Inferior -1 +13 
Nasal Superior -4 +5 
Veins Temporal inferior  -5 -7 
Temporal superior  +6 -5 
Nasal Inferior -5 0 
Nasal Superior 0 +3 
Table 5.10: The percentage change between the mean and median vessel thickness of 







5.5 Visual acuity analysis 
Visual acuity data was not judged to be normally distributed for the MS (no ON) and HV 
groups. Comparisons of each group’s mean HCVA and LCVA scores showed little differences 
between participant groups- differences became evident when comparing the median scores 
of each participant group, as shown in Table 5.11. The MS (no ON) group was found to have 
a smaller median HCVA score in both the left (HV: 56, MS: 50, p-value < 0.001) and right 
(HV: 55, MS: 52, p-value < 0.05) eyes when compared to the HV group. A similar result was 
observed for LCVA scores in both the left (HV: 27, MS: 21, p-value < 0.01) and right (HV: 
25, MS: 19, p-value < 0.001) eyes. The range of scores was greatest in the MS (no ON) group 
for both HCVA and LCVA score, as although the highest scores were similar in all participant 
groups, participants with MS (no ON) would more frequently score poorly when reading from 
both 2.5% and 100% Sloan letter charts. 
 
 
The MS (ON) group was not found to have a significant difference in their HCVA scores in 
either eye when compared to the HV group when using a Mann-Whitney U test. However, 
LCVA scores were found to be significantly reduced in the left eye (HV: 27, MS (ON): 6, p < 
0.01), but not in the right eye (HV: 25, MS (ON): 21, p = 0.1). Medians scores for HCVA and 
 Median visual acuity scores for each participant group (range) 
 Healthy Volunteers MS (no ON) MS (ON) 


































Table 5.11: The difference in median baseline visual acuity scores for MS participants 
when compared to the baseline visual acuity scores of healthy volunteers when using a 
Mann-Whitney U-test, in each eye. OS = left eye, OD = right eye, ON = optic neuritis, N= 
number of participants 
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LCVA were not found to be significantly different between MS participants and participants 
with a clinical history of ON in either eye.  
5.6 Baseline regression analysis  
5.6.1 Baseline OCT  
Globally, the predictors disease and age produced the multivariate model which was most 
representative of the RNFL thickness data in both eyes (OS: adjusted R-squared = 0.15, 
p<0.001, OD: adjusted R-squared = 0.19, p<0.001). This was also the case in all nasal regions 
(see Table 5.12). However, the temporal regions were less consistent e.g., the temporal region 
itself was best described by the univariate model of disease as the only predictor (OS: adjusted 
R-squared=0.15, p<0.001, OD: adjusted R-squared=0.15, p<0.001). The only region for which 
the sex of a participant added predictive power was the inferior temporal of the left eye 
(adjusted R-squared=0.09, p<0.01), but macular volume was best described by all three 
predictors in both eyes (OS: adjusted R-squared=0.08, p<0.01, OD: adjusted R-squared=0.15, 
p<0.001). All models were found to be significant (p<0.01), except when modelling the 
inferior nasal region of both eyes.  
Table 5.13 displays the coefficients for the best fitting model within each region. The effect of 
disease was comparable to the difference in mean values between HV and MS (no ON) groups 
at baseline and was found to be significant (p<0.05) in all regions except the inferior nasal, in 
which the models themselves were not significant. The greatest reduction in RNFL thickness 
attributed to disease was again seen in the inferior temporal (OS: -14µm, p<0.001; OD: -12µm, 
p<0.001) and temporal (OS: -11µm, p<0.001; OD: -12µm, p<0.001) regions. Disease was also 





Adjusted R-Squared value for three linear regression models 
 Disease, age and sex Disease and age Disease 
Region OS OD OS OD OS OD 
Global 0.144*** 0.187*** 0.148*** 0.193*** 0.128*** 0.166*** 
Temporal 0.14*** 0.15*** 0.142*** 0.153*** 0.146*** 0.154*** 
Temporal 
Inferior 0.092** 0.075** 0.089*** 0.078** 0.089*** 0.064** 
Temporal 
Superior 0.043* 0.055* 0.049* 0.06** 0.052** 0.042* 
Nasal 0.08** 0.111*** 0.084** 0.118*** 0.067** 0.105*** 
Nasal Inferior 0.003 0.014 0.011 0.022 0.003 0.02 
Nasal 
Superior 0.066** 0.062* 0.068** 0.063** 0.034* 0.052** 
Macular 
Volume 0.075** 0.146*** 0.068** 0.137*** 0.066** 0.13*** 
 
Although age was included as a predictor in all but one region, it was only found to be a 
significant attributor to RNFL reductions globally (OS: -0.18µm/year, p-value <0.05; OD: -
0.19µm/year, p-value<0.05), as well as in the superior nasal region of the left eye (-
0.38µm/year, p<0.05). Likewise, macular volume and the inferior temporal region of the left 
eye both included sex as a predictor, but despite the models suggesting females have a 
reduction in macular volume and RNFL thickness, sex was not found to be a significant 
predictor. In the regions which played host to the largest changes in RNFL thickness (global 
and all temporal regions) the regression model’s residuals appeared normal, suggesting that 
linear modelling was indeed appropriate for describing the data. The superior nasal region of 
the right eye also appeared normal although no other nasal region shared this normality, 
indicating that the models were less suited to describing data from these regions. 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.12: Adjusted R-squared values for three linear regression models using the 
predictors age, sex and disease. The model highlighted in grey for each region was 








 Results for linear regression models 
  OS OD  
Region  Coefficient p-value Coefficient p-value 
Global 
Disease -9 <0.001 -10 <0.001 
Age -0.18 <0.05 -0.19 <0.05 
Temporal Disease -11 <0.001 -12 <0.001 
Temporal 
Inferior 
Disease -14 <0.001 -12 <0.01 
Age -0.15 0.35 -0.3 0.08 
Sex 5.59 0.22 N/A N/A 
Temporal 
Superior 
Disease -10 <0.01 -8 <0.05 
Age N/A N/A -0.26 0.06 
Nasal 
Disease -7 <0.01 -10 <0.001 
Age -0.19 0.06 -0.18 0.1 
Nasal 
Inferior 
Disease -4 0.34 -8 0.09 
Age -0.26 0.15 -0.19 0.28 
Nasal 
Superior 
Disease -8 <0.05 -8 <0.05 
Age -0.38 <0.05 -0.21 0.11 
Macular 
Volume 
Disease -0.207 <0.01 -0.29 <0.001 
Age -0.003 0.25 -0.004 0.16 
Sex -0.106 0.17 -0.118 0.14 
 
A comparison of the adjusted R-squared values for the raw data and the remodelled data (with 
influential points removed) are shown in Table 5.14, alongside their associated p-values. No 
model that previously lacked significance subsequently gained significance when remodelled. 
In the right eye, the adjusted R-squared value was only improved when remodelling macular 
volume data, which was again best represented by all three predictors. However, in the left eye 
all nasal regions along with the inferior and superior temporal regions benefitted from a higher 
adjusted R-squared value when highly influential data points were removed. Within the nasal  
 
Table 5.13: Linear regression model coefficients and their associated significance 
values for each eye. OS = left eye, OD = right eye 
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region itself, age was deemed to be a significant predictor in remodelled data along with 
disease (see Table 5.15), whereas previously it indicated a trend rather than significance (p = 
0.06). The greatest change in the effect of disease on RNFL thickness was in the nasal region 
of the left eye and the inferior temporal regions of both eyes. However, the coefficients of the 
remodelled data largely remained similar to that of the raw data, suggesting that linear 
modelling of the raw data was sufficiently robust to account for influential data points. 
Table 5.16 displays the results from modelling the MS (no ON) group with length of disease, 
age and sex as predictors of RNFL thickness and macular volume. Few models were found to 
be significant when using permutations of these 3 predictors and the adjusted R-squared values  
 
Adjusted R-Squared values for models with and without influential points 
 OS OD 
 Raw data Remodelled data Raw data Remodelled data 







Global 0.148 <0.001 0.116 <0.001 0.193 <0.001 0.17 <0.001 
Temporal 0.146 <0.001 0.122 <0.001 0.154 <0.001 0.14 <0.001 
Temporal 
Inferior 0.092 <0.01 0.102 <0.01 0.078 <0.01 0.053 <0.05 
Temporal 
Superior 0.052 <0.01 0.055 <0.01 0.06 <0.01 0.047 <0.05 
Nasal 0.084 <0.01 0.123 <0.001 0.118 <0.001 0.113 <0.001 
Nasal 
Inferior 0.011 0.18 0.014 0.16 0.022 0.09 0.021 0.11 
Nasal 
Superior 0.068 <0.01 0.09 <0.01 0.063 <0.01 0.059 <0.01 
Macular 
volume 0.075 <0.01 0.071 <0.05 0.146 <0.001 0.166 <0.001 
Table 5.14: Comparing model statistics for raw and remodelled data (with influential points 
removed). OS = left eye, OD = right eye. 
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selected are shown in Table 5.17. Of the models which were significant, length of disease was 
found to correlate with a thinner RNFL in the global (-0.45µm/year, p-value < 0.05), temporal 
(-0.6µm/year, p-value<0.05) and the inferior temporal (-1.27µm/year, p-value<0.01) regions 
for the right eye. In no other region was length of disease found to be a significant predictor, 
yet in all regions except the inferior and superior nasal regions of the left eye, length of disease 
was found to positively correlate with a thinner RNFL. 
 
 Results for linear regression model once influential data points are 
removed 
 
 OS OD  
Region 











Disease -9 -9 <0.001 -10 -10 <0.001 
Age -0.18 -0.13 0.15 -0.19 -0.14 0.11 
Temporal Disease -11 -10 <0.001 -12 -11 <0.001 
Temporal 
Inferior 
Disease -14 -16 <0.001 -12 -10 <0.05 
Age -0.15 -0.14 0.41 -0.3 -0.24 0.17 
Sex 5.59 4.2 0.36 N/A N/A N/A 
Temporal 
Superior 
Disease -10 -10 <0.01 -8 -8 <0.05 
Age N/A N/A N/A -0.26 -0.2 0.1 
Nasal 
Disease -7 -9 <0.001 -10 -11 <0.001 
Age -0.19 -0.24 <0.05 -0.18 -0.13 0.26 
Nasal Inferior 
Disease -4 -4 0.35 -7 -8 0.07 
Age -0.26 -0.28 0.13 -0.21 -0.13 0.48 
Nasal Superior 
Disease -8 -9 <0.05 -8 -8 <0.05 
Age -0.38 -0.41 <0.01 -0.21 -0.2 0.15 
Macular volume  
Disease -0.207 -0.222 <0.01 -0.29 -0.303 <0.001 
Age -0.003 -0.002 0.43 -0.004 -0.005 0.13 
Sex -0.106 -0.07 0.39 -0.118 -0.11 0.17 
 
Table 5.15: A comparison of raw data coefficients and remodelled data coefficients in 






Despite the regression model for macular volume being significant when using age, sex and 
length of disease as predicators, none of these were found to be significant themselves. 
However, length of disease appears to also positively correlate with a reduced macular volume 
in patients with MS (OS: -0.009mm3/year, p= 0.29; OD: -0.013mm3/year, p=0.12). The rate 
of reduction due to MS was greater than that attributed to aging (OS: -0.005mm3/year, p=0.29; 
OD: -0.008mm3/year, p=0.13) when modelling macular volume. Fingolimod was initially 
included as a predictor for those that were prescribed it during the course of the study, however 
in no region was it found to either be significant or increase the predictive power of the models, 
so it was excluded from the final regression analysis to avoid overfitting.   
 Adjusted R-Squared value for three linear regression models 
 Length of disease, Age, Sex Length of disease, Age Length of disease 
Region OS OD OS OD OS OD 
Global -0.025 0.025 -0.008 0.037 0.006 0.052* 
Temporal -0.001 0.065 -0.008 0.065 -0.002 0.073* 
Temporal 
Inferior 0.023 0.083* 0.003 0.095* 0.012 0.103** 
Temporal 
Superior -0.04 -0.016 -0.022 -0.013 -0.007 0 
Nasal -0.021 -0.026 -0.003 -0.025 0.002 -0.012 
Nasal Inferior -0.012 -0.022 -0.014 -0.021 -0.015 -0.012 
Nasal 
Superior 0.034 0.032 0.035 0.016 -0.01 -0.005 
Macular 
Volume 0.038 0.096* 0.026 0.074 0.031 0.059* 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.16: Adjusted R-squared values for three models, investigating how length of 
disease affects RNFL thickness and macular volume. The model highlighted in grey 










Results for linear regression model 
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Global LoD -0.29 0.25 -0.45 <0.05 
Temporal 
LoD -0.4 0.18 -0.6 <0.05 
Age 0.17 0.32 N/A N/A 
Sex 5 0.24 N/A N/A 
Temporal 
Inferior 
LoD -0.84 0.09 -1.27 <0.01 
Age 0.27 0.34 N/A N/A 
 Sex 11 0.15 N/A N/A 
Temporal 
Superior LoD -0.32 0.45 -0.33 0.31 
Nasal LoD -0.26 0.3 -0.13 0.6 
Nasal Inferior 
LoD 0.12 0.8 -0.22 0.6 
Age -0.34 0.23 N/A N/A 
Sex -8 0.3 N/A N/A 
Nasal Superior 
LoD 0.05 0.92 -0.05 0.88 
Age -0.5 0.06 -0.32 0.09 
Sex N/A N/A -8 0.17 
Macular Volume 
LoD -0.009 0.29 -0.013 0.12 
Age -0.005 0.29 -0.008 0.13 
Sex -0.164 0.20 -0.193 0.14 
Table 5.17: Coefficients and significance values for models in each eye. OS = left eye, 
OD = right eye, LoD = length of disease 
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5.6.2 Baseline UWF-SLO  
The adjusted R-squared values when using the predictors age, sex and disease to model for 
vessel width in each peripapillary quadrant of the retina are shown in table 5.18, with the 
model selected for further coefficient analysis highlighted in grey. The model with the largest 
adjusted R-squared value when modelling for arterial data was that of the inferior nasal region 
of the right eye (adjusted R-squared: 0.095, p<0.01). However, much like the regression 
models created for OCT data, adjusted R-squared values were generally very small and the 
models which best describe vessel width varied from region to region and between the left and 
right eye. Despite this, arterial width models were found to be significant with exception of 
the superior nasal quadrant in both sets of eyes and the superior temporal quadrant of the left 
eye. In the venous width modelling (Table 5.20), only the univariate model for inferior nasal 
data in the right eye was found to have significance. Unlike RNFL thickness data, age was 
more often considered a positive contributor to the model when using vessel width as a 
response variable.  
As shown in Table 5.19, a reduced mean arterial thickness in the MS (no ON) group can be 
seen when compared to the HVs in all models, although the coefficients of disease were only 
found to be significant in the inferior nasal quadrant (OS: -0.0053mm, p-value < 0.05; OD: -
0.0079mm, p-value < 0.01) where the difference was greatest. When included as a predictor 
in the regression models, age was found to be associated with a reduced arterial thickness (per 
year) with exception of the inferior nasal quadrant of the right eye. Though age was not 
significant in the superior nasal quadrant it was close to significance in the inferior temporal 
region of the right eye (-3e-04mm/year, p-value = 0.05), and as a predictor age was significant 
in all other regions for which it was included. Sex was not found to be a significant confounder 
when included in the models but was consistent in describing females as having thicker mean 





Adjusted R-Squared value for three models of arterial data 
 Disease, age and sex Disease and age Disease 
Region OS OD OS OD OS OD 
Temporal 
Inferior 0.041* 0.038 0.045* 0.042* 0 0.017 
Temporal 
Superior 0.019 0.049* 0.027 0.042* -0.001 -0.005 
Nasal Inferior 0.03 0.095** 0.039 0.086** 0.046* 0.061** 
Nasal 
Superior -0.002 -0.005 -0.006 0 -0.007 0.006 
Results for linear regression models of arterial data  
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
Disease -0.0018 0.55 -0.0044 0.15 
Age -0.0003 <0.05 -3e-04 0.05 
Temporal 
Superior 
Disease -0.0015 0.57 -7e-04 0.8 
Age -2e-04 <0.05 -3e-04 <0.01 
Sex N/A N/A 0.0042 0.16 
Nasal Inferior 
Disease -0.0053 <0.05 -0.0079 <0.01 
Age N/A N/A 2e-04 <0.05 
Sex N/A N/A 0.0044 0.16 
Nasal Superior 
Disease -0.0005 0.78 -0.0027 0.18 
Age -1e-04 0.33 N/A N/A 
Sex 0.0026 0.22 N/A N/A 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.18: Adjusted R-squared values for three linear regression models. The model 
highlighted in grey for each quadrant was selected for coefficient analysis. OS = left eye, 






Table 5.19: Coefficients and significance values for arterial models in each eye. OS 






Adjusted R-Squared value for three models for veins 
 Disease, age and sex Disease and age Disease 
Region OS OD OS OD OS OD 
Temporal 
Inferior 0.032 -0.019 0.004 -0.01 0.012 -0.008 
Temporal 
Superior -0.004 0.014 -0.01 0.002 -0.004 -0.008 
Nasal Inferior 0.042 0.027 0.033 0.035 0.028 0.027* 
Nasal 
Superior -0.0066 0.0016 0.001 0.008 0.008 0.016 
Results for linear regression model in vein data  
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
Disease -0.0042 0.12 1e-04 0.81 
Age 0 0.77 N/A N/A 
Sex 0.0066 <0.05 N/A N/A 
Temporal 
Superior 
Disease -0.0021 0.56 4e-04 0.9 
Age -1e-04 0.6 -2e-04 0.16 
Sex 0.0053 0.19 0.0053 0.11 
Nasal Inferior 
Disease -0.0051 <0.05 -0.0054 <0.05 
Age 1e-04 0.22 1e-04 0.16 
Sex 0.0038 0.18 N/A N/A 
Nasal Superior Disease -0.0029 0.16 -0.0043 0.08 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.20: Adjusted R-squared values for three linear regression models. The 
model highlighted in grey for each quadrant was selected for coefficient analysis.  






Table 5.21: Coefficients and significance values for vein models in each eye. OS = left 
eye, OD = right eye 
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Baseline regression models for venous data also showed disease to correlate with a reduced 
vessel width in all quadrants of the left eye and both nasal quadrants of the right eye. The 
greatest difference between the MS (no ON) and HV groups where once again found in the 
inferior nasal quadrant of the retina, with significance and similar coefficients for both eyes 
(OS: -0.0051, p-value < 0.05; OD: -0.0054, p-value < 0.05), despite neither model being 
significant. Unlike arterial data, age was not found to be a significant confounder in any model 
and the effect of age on mean vein width was inconsistent throughout the quadrants. Once 
again, being female was found to associate with wider vessels (between 0.0038mm-
0.0066mm), although sex was only a significant predictor in the inferior temporal quadrant of 
the left eye (0.0066mm, p-value < 0.05). 
The remodelled data, once influential data points had been removed, is presented in Tables 
5.22 and 5.23. While the residual plots for each model were assessed to be normal on visual 
inspection and therefore indicate that linear regression models suitably represent the data, in 
some quadrants the adjusted R-squared values were improved when the data was remodelled. 
For example, right eye data for venous width saw both nasal models benefit from a higher 
adjusted R-squared value as well as gaining significance, whereas the inferior temporal 
quadrant of the OS arterial data lost significance when remodelled. Despite 3 of the 4 arterial 
quadrant models being improved in the right eye by remodelling, only the superior nasal 
quadrant gained significance.  
Comparing the remodelled coefficients with those from the raw dataset for arterial width data 
(see Table 5.22) saw three circumstances where the remodelled coefficient of disease changed 
from a negative to a positive value, indicating a thickening of the arteries in individuals with 
MS (no ON), however all three of these coefficients have large p-values and lack evidence of 
a statistically significant effect. Disease coefficients that were significant or close to 
significance changed little in the remodelled data, and no disease coefficient which previously 




Adjusted R-Squared values for arterial models with and without influential points 
 OS OD 
 Raw data Remodelled data Raw data Remodelled data 






Inferior 0.045 <0.05 0.034 0.06 0.042 <0.05 0.042 <0.05 
Temporal 
Superior 0.027 0.07 0.028 0.07 0.049 <0.05 0.055 <0.05 
Nasal Inferior 0.046 <0.05 0.051 <0.05 0.095 <0.01 0.097 <0.01 
Nasal 
Superior -0.002 0.43 -0.003 0.46 0.006 0.18 0.018 0.08 
Results for arterial linear regression models once remodelled 
  OS OD  













Disease -0.0018 1e-04 0.98 -0.0044 -0.0041 0.21 
Age -0.0003 -0.0003 <0.05 -3e-04 -3e-04 0.06 
Temporal 
Superior 
Disease -0.0015 -5e-04 0.86 -7e-04 8e-04 0.75 
Age -2e-04 -2e-04 <0.05 -3e-04 -3e-04 <0.01 
Sex N/A N/A N/A 0.0042 0.0028 0.36 
Nasal Inferior 
Disease -0.0053 -0.0055 <0.05 -0.0079 -0.0085 <0.01 
Age N/A N/A N/A 2e-04 2e-04 0.16 
Sex N/A N/A N/A 0.0044 0.0042 0.17 
Nasal 
Superior 
Disease -0.0005 0.0008 0.68 -0.0027 -0.0036 0.08 
Age -1e-04 -1e-04 0.52 N/A N/A N/A 
Sex 0.0026 0.003 0.17 N/A N/A N/A 
Table 5.22: Comparing model statistics for raw and remodelled arterial data (with 
influential points removed), as well as the coefficients produced from both raw data and 




Adjusted R-Squared value for venous models with and without influential points 
 OS OD 
 Raw data Remodelled data Raw data Remodelled data 






Inferior 0.032 0.08 0.035 0.08 -0.008 0.81 -0.009 0.84 
Temporal 
Superior -0.004 0.47 -0.014 0.7 0.014 0.19 0.014 0.2 
Nasal Inferior 0.042 0.08 -0.011 0.56 0.035 0.05 0.044 <0.05 
Nasal 
Superior 0.008 0.162 0.008 0.17 0.016 0.08 0.0316 <0.05 
Results for venous linear regression models once remodelled  
  OS OD  













Disease -0.0042 -0.0046 0.1 7e-04 6e-04 0.84 
Age 0 0 0.78 N/A N/A N/A 
Sex 0.0066 0.0068 <0.05 N/A N/A N/A 
Temporal 
Superior 
Disease -0.0021 -0.0076 0.84 4e-04 0.0017 0.58 
Age -1e-04 -1e-04 0.5 -2e-04 -2e-04 0.09 
Sex 0.0053 0.0038 0.38 0.0053 0.0038 0.29 
Nasal Inferior 
Disease -0.0051 -0.0031 0.2 -0.0054 -0.0058 <0.05 
Age 1e-04 1e-04 0.41 1e-04 2e-04 0.14 
Sex 0.0038 1e-04 0.75 N/A N/A N/A 
Nasal 
Superior Disease -0.0029 -0.003 0.17 -0.0043 -0.0055 <0.05 
Table 5.23: Comparing model statistics for raw and remodelled venous data (with 
influential points removed), as well as the coefficients produced from both raw data and 
remodelled data (with associated p-values for each remodelled coefficient)  
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predictor for arterial data, the coefficients remained the same in all quadrants but lost 
significance in the inferior nasal quadrant of the right eye. Finally, where included as a 
predictor, the effect of being female resulted in an increase in arterial thickness, but once more 
the coefficients were not judged to be significant. With the exception of quadrants where the 
disease coefficient was not significant in either the raw or remodelled data, the remodelled 
data suggests that linear regression models were still appropriate and robust in representing 
the data collected. 
For venous width data (see table 5.23), the disease coefficient in the nasal superior quadrant 
of the right eye showed evidence of an effect, which was previously not apparent in the raw-
data models. Contrary to this, in the inferior nasal quadrant of the left eye, the disease 
coefficient lacked evidence of an effect when remodelled. However, unlike arterial data the 
effect of disease on vein width remained consistent in each of the quadrants, though some 
changes were seen in the magnitude of this effect, the biggest being in the superior temporal 
quadrants of both eyes. The effect of age as a predictor (where included) also remained 
consistent within each quadrant, as was the case with sex although the magnitude of the change 
in the three models for which sex was included was smaller in all the remodelled datasets. 
The MS (no ON) data was separated and modelled with three predictors: length of disease, 
age and sex. An additional binomial predictor representing whether an individual was 
prescribed Fingolimod during the extent of the study was also included in the analysis but in 
no circumstances did its inclusion positively contribute to the description of the datasets. The 
resulting adjusted R-squared values are shown in table 5.24 and 5.26, with the only significant 
models being from the arterial dataset in the inferior temporal quadrant. When examining the 
coefficients produced from each model, we see that length of disease was only significant in 
the inferior temporal quadrant of the left eye for arterial data, whilst no other length of disease 
coefficient for any vessel type was similarly significant. The effect of length of disease on 
vessel width was found to be inconsistent across all quadrants, with half of the quadrants 
suggesting thinner vessels and half suggesting thicker vessels or no change. When included as 
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a predictor, age was determined to be significant again for arterial data in the inferior temporal 
quadrants of both eyes. Despite a lack of significance in other regions, in all circumstances 
excluding the inferior nasal quadrants for venous data, age had a thinning effect per year on 
vessel widths. In the three quadrants for which sex was included as a predictor, the effect was 




Adjusted R-Squared value for three arterial models 
 Length of disease, Age, 
Sex 
Length of disease, Age Length of disease  
Region OS OD OS OD OS OD 
Temporal Inferior 0.241*** 0.132* 0.256*** 0.088* 0.001 -0.013 
Temporal Superior 0.005 0.067 0.02 0.043 -0.008 -0.012 
Nasal Inferior -0.034 -0.055 -0.022 -0.033 0.009 -0.022 
Nasal Superior 0.041 -0.018 0.06 -0.006 0.044 0.004 
 
 Results for linear regression models in arterial width data 
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
LoD 6.9e-04 <0.05 3.7e-04 0.29 
Age -7.5e-04 <0.001 -4.7e-04 <0.05 
Sex N/A N/A 0.0105 0.06 
Temporal 
Superior 
LoD -1.1e-04 0.73 -7e-05 0.84 
Age -2.7e-04 0.11 -3.3e-04 0.06 
Sex N/A N/A 0.0077 0.12 
Nasal Inferior LoD 3.7e-04 0.26 -5e-05 0.87 
Nasal Superior 
LoD -3e-04 0.15 -2.7e-04 0.28 
Age -1.4e-04 0.18 N/A N/A 
Table 5.25: Coefficients and significance values for arterial models in each eye. OS = left 
eye, OD = right eye, LoD = length of disease 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.24: Adjusted R-squared values for three linear regression models. The model 
highlighted in grey for each quadrant was selected for coefficient analysis. OS = left eye, 










Adjusted R-Squared value for three venous models 
 Length of disease, Age, 
Sex 
Length of disease, Age Length of disease  
Region OS OD OS OD OS OD 
Temporal Inferior 0.024 -0.005 0.042 0.007 0.006 -0.018 
Temporal Superior -0.002 0.042 0.014 0.044 -0.006 0.013 
Nasal Inferior 0.054 -0.026 -0.03 -0.011 -0.027 -0.017 
Nasal Superior -0.052 -0.03 -0.032 -0.023 -0.019 -0.013 
 
 Results for linear regression models in venous width data 
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
LoD 4.5e-04 0.13 6e-05 0.87 
Age -2.6e-04 0.09 -3.1e-04 0.13 
Temporal 
Superior 
LoD -1.6e-04 0.65 5.4e-04 0.1 
Age -2.6e-04 0.15 -2.8e-04 0.09 
Nasal Inferior 
LoD -1.7e-04 0.62 5e-05 0.85 
Age 2.3e-04 0.19 1.6e-04 0.26 
Sex 0.011 0.05 N/A N/A 
Nasal Superior LoD 0 0.99 -1.3e-04 0.62 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.26: Adjusted R-squared values for three linear regression models. The model 
highlighted in grey for each quadrant was selected for coefficient analysis. OS = left eye, 
OD = right eye. 
 
Table 5.27: Coefficients and significance values for venous models in each eye. OS = 
left eye, OD = right eye, LoD = length of disease 
 92 
5.6.3 Baseline visual acuity  
The three variables (age, sex and disease) were used as predictors of LCVA and HCVA scores 
in order to determine the effects of each on the functionality of someone’s retina. The adjusted 
R-squared values for each model (as shown in Table 5.28) indicate that for HCVA data, using 
all three predictors was most useful in predicting variation in both eyes. However, the 
increased effect that MS (no ON) has on LCVA score was reflected in LCVA data being best 
described by a univariate model of disease alone. All models were significant in their 
description of the data. The coefficients for disease (see Table 5.29) were significant and 
negative for both HCVA (OS: -5, p-value<0.05; OD: -5, p-value<0.01) and LCVA (OS: -6, p-
value<0.01; OD: -6, p-value<0.001) data, being the only significant coefficients found during 
the modelling. Of the other predictors included, age and being female had a negative effect on 
the HCVA score of a participant.   
On assessment of the residuals of the raw data models, all were deemed to be normal 
supporting the use of linear regression in modelling the datasets. Remodelling of the data with 
the removal of influential data points showed raw datasets to have a greater adjusted R-squared 
value and a lower p-value than the remodelled data (see Table 5.30). The coefficients of 
disease were themselves similar to the raw data models, with an additional drop in LCVA 
score of 1 letter attributed to disease in left eye when compared to raw data models (Table 
5.31). Once more, to investigate how length of disease may affect the decline in both LCVA 
and HCVA in patients with MS (no ON), it was incorporated into modelling of the MS (no 
ON) data. The resulting adjusted R-squared values were very small (see Table 5.32). The 
coefficients in the unanimously univariate models selected, though in all cases lacking 
evidence of an effect, suggested a slight positive correlation between length of disease and 













Adjusted R-Squared value for three models for HCVA and LCVA scores 
 Disease, age and sex Disease and age Disease 
Region OS OD OS OD OS OD 
HCVA 0.051* 0.075** 0.049* 0.071** 0.041* 0.064** 
LCVA 0.049* 0.079** 0.056* 0.087** 0.062** 0.09*** 
 
 Results for linear regression models of visual acuity data in both 
eyes   
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
HCVA 
Disease -5 <0.05 -5 <0.01 
Age -0.12 0.15 -0.1 0.17 
Sex -3 0.27 -3 0.23 
LCVA Disease -6 <0.01 -6 <0.001 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.28: Adjusted R-squared values for three linear regression models. The model 







Table 5.29: Coefficients and significance values for HCVA and LCVA models in each 




Adjusted R-Squared values for HCVA and LCVA models with and without 
influential points 
 OS OD 
 Raw data Remodelled data Raw data Remodelled data 
Region R-
squared 





HCVA 0.051 <0.05 0.045 <0.05 0.075 <0.01 0.07 <0.05 
LCVA 0.062 <0.01 0.046 <0.05 0.09 <0.001 0.07 <0.01 
 
 Results for linear regression model 
 
 OS OD  
Region 











Disease -5 -5 <0.05 -5 -5 <0.05 
Age -0.12 -0.1 0.22 -0.1 -0.1 0.15 
Sex -3 -2 0.33 -3 -3 0.18 
LCVA Disease -6 -5 <0.05 -6 -6 <0.01 
Table 5.30: Comparing raw and remodelled data coefficients models. OS = left eye, OD 
= right eye 
Table 5.31: Comparing raw and remodelled data coefficients for HCVA and LCVA 
















Adjusted R-Squared values for three models for HCVA and LCVA scores 
 LoD, age and sex LoD and age LoD 
Region OS OD OS OD OS OD 
HCVA -0.028 -0.064 -0.018 -0.043 0.001 -0.021 
LCVA 0.007 -0.05 0.027 -0.033 0.047 -0.013 
 
 Results for linear regression model of visual acuity data in both 
eyes   
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
HCVA LoD 0.25 0.31 0.05 0.85 
LCVA LoD 0.44 0.07 0.14 0.54 
p-values: * <0.05, **<0.01, ***<0.001 
Table 5.32: Adjusted R-squared values for three linear regression models. The model 
highlighted in grey for each eye was selected for coefficient analysis. OS = left eye, 






Table 5.33: The coefficients when modelling HCVA and LCVA using LoD (length of 




The findings presented in this chapter offer the first indication of MS affecting the width of 
peripheral retinal blood vessels, with statistically significant evidence of an effect found in the 
inferior nasal quadrant. This finding agrees with the small amount of research previously 
performed on the retinal vasculature close to the optic nerve head in patients with MS, however 
it further identifies both thinner arteries and veins separately whilst using quadrant-based 
analysis to identify a profile of vessel width reduction. Comparisons made of baseline data do 
not indicate whether vascular changes occur over a period of time or acutely at disease onset, 
which is the motivation for utilising longitudinal data. Baseline analysis also confirmed reports 
in the literature of RNFL thickness reductions and macular volume loss measured on OCT and 










Longitudinal Data Analysis 
6.1 Introduction 
In order to determine whether the anatomical differences reported in chapter 5 occur 
longitudinally or over a short time period early in the disease course (as per hypothesis 3), 
follow-up data was used to investigate the rates-of-change within each of the participant 
groups, with the results reported in this chapter. Analysis will show the importance of using 
linear modelling for follow-up data and how the rate-of-change seen in OCT data is found to 
be accelerated as a result of MS. UWF-SLO data analysis is less conclusive but may indicate 
a similar longitudinal change as that seen in RNFL thickness and macular volume data on 
OCT.  
6.2 Data cleaning  
Of the healthy controls included in this study, two fell pregnant during the time between 
baseline and follow-up scan. Both these participants presented with a significantly thicker 
RNFL when scanned during pregnancy: an anatomical change which has been reported, 
though scarcely, in the literature (87). Due to this thickening of the RNFL, scans from during 
the pregnancy were excluded from follow-up analysis to maintain a consistent and fair 
approach to data handling. A postnatal scan was attained for one of these participants, which 
was included in the analysis under the assumption that any anatomical changes related to 
pregnancy had then subsided. The total numbers of participants which were scanned at least 
one further time after baseline are shown in table 6.1.  Age range and median age are again 
slightly larger in the MS group, with more participants in this group having a usable follow-
up scan than the HV group. Visual acuity data was collected at every available opportunity but 
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was dependent on participants remembering to bring any glasses/contact lenses worn during 
the baseline imaging sessions; vision with corrective lenses was assumed to be consistent 
(20/20) throughout the study even if a participant had changed their lens prescription, however 
VA could not be compared for a patient between sessions if they had uncorrected vision for 
their follow-up reading having had corrected vision for their first. 
 
Of the OCT outliers, 3 were caused due to the SPECTRALIS “progression” setting not being 
activated, causing incongruent positioning of peripapillary regions in follow-up scans. For one 
participant from the MS (no ON) group this meant they no longer had both baseline and 
follow-up scans, and their OCT data was excluded from this part of the analysis. The other 2 
participants had an adequate number of scans so that even when excluding their baseline scans, 
they still had enough data for the follow-up analysis. For vessel analysis: despite manual 
removal of outliers as outlined in chapter 4, and the manual selection of the 8 major vessels 
used for analysis in each UWF-SLO image, outliers for rate-of-change were still investigated 
Characteristics Patients with MS 
(N = 69) 
Healthy Volunteers 
(N = 64) 
Median Age  44 41 
Age range 20-79 24-60 
Male 18 14 
Female 51 50 
History of ON (No. patients) 15 0 
History of ON (No. Eyes)  17 (OD 8, OS 9) 0 
Relapse-remitting  60 N/A 
Primary progressive 2 N/A 




Table 6.1: Adjusted group demographics for longitudinal analysis. ON = Optic Neuritis, OS 
= left eye, OD = right eye. *These include: Fingolimod, Tecfidera, Dimethylfumerate, 
Copaxone, Plegridy, Alemtuzimab and Tysabri 
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for each quadrant. Of the outliers, 8 were due to erroneous vessel selection i.e. a different 
vessel or section of vessel being used to calculate the rate-of-change in width. This was due to 
one of three things: 
• OD diameter varying greatly between scans due to incorrect manual segmentation of 
the OD. This error would be exaggerated when calculating the ring within which 
vessel width measurements were being recorded 
• Variations in scan quality meaning a vessel was not within the FOV of an image, yet 
it was in other images 
• Subtle variations in the vessel path due to the binary maps not being identical in each 
image 
In such circumstances, the appropriate vessel selection was corrected were possible or 
removed when not, and the rate-of-change subsequently recalculated. All other suspected 
outliers were deemed to be valid rates-of-change measurements of vessel width and as such 
were included in the analysis. Finally, the outliers produced from visual acuity analysis were 
also investigated manually. Of the outliers, only one participant’s data was removed prior to 
analysis as this individual wore spectacles inconsistently throughout the follow-up sessions 
meaning their scores could not be compared. All other data was included in the analysis.  
6.3 OCT analysis   
Though there were several regions with normally distributed RNFL thickness data, this was 
not true of all regions. For example, inferior nasal, superior nasal and macular volume 
appeared normally distributed in left eye data for HVs but not for the MS (no ON) group, 
therefore making direct comparisons with a Student’s t-test inappropriate. Table 6.2 displays 
the median rate-of-change for each peripapillary RNFL region for the HV, MS (no ON) and 
MS (ON) groups. Despite baseline RNFL data presenting the temporal regions of the retina as 
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being most effected by MS, the largest annual change in RNFL thickness for the left eye was 
in the inferior nasal region (OS: -1.06µm/year), with the temporal regions generally showing 
  
 Median rate of change in RNFL thickness in µm/year (IQR) 
 Healthy Volunteers MS (no ON) MS (ON) 
Region OS OD OS OD OS OD 




























































































Median rate of change in macular volume in mm#/year (IQR) 
Healthy Volunteers  MS (no ON) MS (ON) 













p-values: * <0.05, **<0.01, ***<0.001 when comparing MS (no ON) and MS (ON) 
groups with HVs 
Table 6.2: Median annual RNFL thickness and macular volume changes seen in the three 
participant groups. OS = left eye, OD = right eye, ON = optic neuritis, MS = multiple 
sclerosis, SD = standard deviation 
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smaller annual changes when compared to the nasal regions for individuals in the MS (no ON) 
group. Left eye data for MS (no ON) did show an annual decrease in all but the temporal and 
superior temporal regions, however this pattern was not seen in the right eye, where only the 
superior temporal region showed annual change (OD: -0.05µm/year). A median annual 
reduction in macular volume was however shown in both eyes of the MS (no ON) group (OS: 
-0.028mm3/year OD: -0.02mm3/year) along with both eyes of the MS (ON) group (OS: -
0.028mm3/year OD: -0.025mm3/year).   
The HV group showed either no change or an annual increase in RNFL thickness and macular 
volume in both eyes. When comparing the rates-of-change of the MS (no ON) and HV groups 
statistically via a Mann-Whitney U test, we found there to be a significant difference in values 
in both sets of eyes globally (OS: p<0.001; OD: p<0.01) and in the inferior nasal regions (OS: 
p<0.001; OD: p<0.05). This was also true of the temporal, superior temporal, nasal and 
superior nasal regions of the left eye, suggesting an increased rate of thinning in participants 
with MS (no ON). Despite the low numbers in the MS (ON) group, we still see a significant 
difference between this group and the HVs in rate-of-change of macular volume and temporal 
RNFL thickness (this being the region which showed the greatest amount of annual thinning 
(OS: -0.95µm/year; OD: -1.56µm/year)) in both eyes, as well as globally in the right eye. The 
median rate-of-change in the MS (ON) group showed annual thinning in all but three regions, 
and the annual change was greater than seen in MS (no ON) participants in 9 of the 14 
peripapillary regions tested.  
6.4 UWF-SLO analysis  
Some quadrant data was found to be normally distributed, but there were also many sections 
which were not e.g., all but the superior nasal quadrant of right eye MS (no ON) data. As 
shown in Table 6.3, the rate-of-change of arterial thickness in the MS (no ON) group was not 
consistent throughout the peripapillary quadrants; despite baseline data indicating a reduction 
of vessel calibre for participants with MS (no ON) when compared to the HV group, 
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longitudinal analysis shows an annual decline in arterial width in 3 of the 8 quadrants 
investigated. The HV group did however show a median annual thinning of arterial vessels, 
with all but the inferior temporal region of the left eye indicating a fall in vessel width year on 
year. The only region for which there was a significant difference (p<0.01) in the rate-of-
change of arterial thinning was the superior temporal when comparing left eye HV (OS: -
3.6e4mm/year) and MS (ON) (OS: 0.0055mm/year) data. As with the MS (no ON) group, MS 
(ON) data showed a median annual arterial thinning in only a minority of quadrants.  
No significant effects were found in the venous data when comparing the three participant 
groups, where an annual decrease in vessel thickness was seen in only 2 of the MS (no ON) 
quadrants and 2 of the MS (ON) quadrants (Table 6.4). In both vessel categories, the variation 
in results is reflected by the large interquartile range (IQR) relative to the small rate-of-change 
values, and the MS (ON) group’s veins did not appear to thin over time despite the lower width 
values seen in the baseline vessel analysis. The HV group showed an increase in vein width 




Median rate of change of arterial thickness in mm/year (IQR)  
 Healthy volunteers MS (no ON) MS (ON) 

























































p-values: * <0.05, **<0.01, ***<0.001 when comparing MS (no ON) and MS (ON) groups 
with HVs 
Table 6.3: Median annual arterial thickness changes seen in the three participant groups. OS 




6.5 Visual acuity analysis 
Normality of the data was not consistently found when analysing the three participant 
groups which meant Mann-Whitney U tests were used for analysis. HCVA data 
showed an annual increase in the left eye for both HVs and those in the MS (ON) group 
(see Table 6.5), whereas left eye data for the MS (no ON) group showed an annual 
decrease. Right eye data showed median HCVA to be unchanged in the HV group year 
on year but showed a drop in both MS groups.  
Both eyes in the HV group showed an annual rise in LCVA, but the greatest rise was 
seen in the right eye of the MS (no ON) group, with the left eye in the same group 
showing no change. The MS (ON) group showed a lack of change in the right eye, but 
an annual increase in the left eye. Neither of the MS groups showed a significant 
difference in the rate of change of HCVA or LCVA score for either eye when 
 
Median rate-of-change of venous thickness in mm/year (IQR)  
 Healthy volunteers MS (no ON) MS (ON) 

























































p-values: * <0.05, **<0.01, ***<0.001 when comparing MS (no ON) and MS (ON) groups 
with HVs 
Table 6.4: Median annual venous thickness changes seen in the three participant groups.  OS 
= left eye, OD = right eye, ON = optic neuritis, MS = multiple sclerosis, IQR = interquartile 
range 
 104 
compared to the HV group. Once again, IQRs were often large, especially in the MS 
(no ON) group for LCVA data. 
 
  
6.6 Regression analysis   
6.6.1 Longitudinal OCT  
The adjusted R-squared values for regression models of longitudinal changes in RNFL 
thickness and macular volume are shown in table 6.6. As was true with baseline regression 
models, despite low adjusted R-squared values there were significant models produced for 
multiple regions: in four circumstances we see a lack of evidence of an effect, three of which 
are from the temporal regions where data was best represented by a univariate model with 
disease/no disease acting as the lone predictor. However, generally left eye data was better 
represented by univariate models with only the inferior nasal region including the predictors 
age and sex, whereas right eye data was better described by multivariate models in 5 of the 8 
datasets. 
 Median change in visual acuity scores for group demographics (IQR) 
 Healthy Volunteers MS (no ON) MS (ON) 
Snellen chart OS OD OS OD OS OD 
Full contrast (100%) 1 (5) 0 (8) -1 (7) -1 (8) 6 (12) -1 (3) 
Low contrast (2.5%) 1 (6) 3 (8) 0 (17) 5 (12) 4 (2) 0 (11) 
p-values: * <0.05, **<0.01, ***<0.001 when comparing MS (no ON) and MS (ON) 
groups with HVs 
Table 6.5: Median annual HCVA and LCVA changes seen in the three participant groups.  




The subsequent coefficient values from each of the selected models are shown in table 6.7. 
Disease was a significant coefficient in all but the inferior temporal models of both eyes and 
the superior temporal region of the right eye. The only region for which disease did not have 
a negative coefficient (indicating that disease caused an increase in the annual rate of RNFL 
thinning) was the inferior temporal region of the left eye. Nasal regions seemed to be more 
effected by disease than temporal regions when modelling rates-of-change, having the largest 
absolute coefficients in the inferior nasal regions of the left eye (OS: -1.32, p<0.05; OD) and 
superior nasal region of the right eye (OS: -1.11, p<0.05; OD: -1.13, p<0.01). An annual global 
reduction of RNFL thickness in both eyes (OS: -0.98, p<0.001; OD: -0.77, p<0.01) was also 
found.  
 Adjusted R-Squared value for three RNFL data regression models 
 Disease, Age, Sex Disease, Age Disease 
Region OS OD OS OD OS OD 
Global 0.07** 0.064* 0.078** 0.07** 0.084*** 0.045* 
Temporal 0.048* 0.022 0.056 * 0.025 0.064** 0.033* 
Temporal 
Inferior -0.017 -0.011 -0.011 -0.013 -0.006 -0.007 
Temporal 
Superior 0.014 0.008 0.023 0.014 0.028* 0.018 
Nasal 0.034 0.022 0.033 0.028 0.036* 0.023 
Nasal 
Inferior 0.053* 0.069** 0.046* 0.077** 0.03* 0.034* 
Nasal 
Superior 0.012 0.052 * 0.018 0.053* 0.026* 0.044* 
Macular 
Volume 0.066 * 0.083** 0.065** -0.073** 0.071** 0.08** 
p-values: * <0.05, **<0.01, ***<0.001  
Table 6.6: Adjusted R-squared values when modelling annual changes in RNFL thickness 
and macular volume. The model highlighted in grey for each region was selected for 
coefficient analysis. OS = left eye, OD = right eye, ON = optic neuritis, MS = multiple 
sclerosis, IQR = interquartile range 
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When included as a predictor, both sex and age caused a reduction in the annual rate of RNFL 
thinning, however sex was never a significant predictor and age was only significant in the 
global (OD: 0.02, p<0.05) and inferior nasal (OS: 0.04, p=0.07; OD: 0.04, p<0.05) regions of 
the right eye. Macular volume was shown to reduce at a higher annual rate for individuals with 
MS (no ON), with disease coefficients being significant in both eyes (OS: -0.047, p<0.01; OD: 
-0.042, p<0.01). Neither age nor sex appeared to have a significant effect on the rate-of-change 
  Results for linear regression models of longitudinal RNFL data 
  OS OD  
Region  Coefficient p-value Coefficient p-value 
Global 
Disease -0.98 <0.001 -0.77 <0.01 
Age N/A N/A 0.02 <0.05 
Temporal Disease -0.8 <0.01 -0.66 <0.05 
Temporal 
Inferior Disease 0.3 0.56 -0.17 0.66 
Temporal 
Superior Disease -1.01 <0.05 -1.02 0.08 
Nasal 
Disease -1.2 <0.05 -0.78 <0.05 
Age N/A N/A 0.02 0.21 
Nasal Inferior 
Disease -1.32 <0.05 -1.06 <0.01 
Age 0.04 0.07 0.04 <0.05 
Sex 0.9 0.19 N/A N/A 
Nasal Superior 
Disease -1.11 <0.05 -1.13 <0.01 
Age N/A N/A 0.02 0.15 
Macular 
Volume 
Disease -0.047 <0.01 -0.042 <0.01 
Age N/A N/A 0 0.67 
Sex N/A N/A 0.022 0.14 
Table 6.7: Coefficient values and their associated p-values from remodelling RNFL 
thickness and macular volume data with rate-of-change as the response variable. OS = left 
eye, OD = right eye 
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of macular volume and the effect of disease looks to have been masked when merely 
calculating the average rate-of-change in the MS (no ON) group as per table 6.2. 
As with the baseline data, to verify the use of the models created, the influential data points 
were removed from the dataset and the remaining data was remodelled, the results from which 
are displayed in tables 6.8 and 6.9. Adjusted R-squared values remained similar but narrowly 
improved in 7 of the 16 models. In only one region (nasal region of the right eye) did a model 
become significant when it otherwise was not in the raw data models. This suggests that the 
models are again robust enough to describe the data collected irrespective of influential data 
points. Likewise, the coefficients produced in each region’s remodelled data were similar to 
that of the raw coefficients, with the only coefficient gaining significance after remodelling 
being age in the inferior nasal region of the left eye. 
The adjusted R-squared values when using length of disease as a predictor for MS (no ON) 
data are displayed in table 6.10: the values are low and only 3 models were deemed significant, 
all of which were in the right eye (global, nasal and inferior nasal). The subsequent estimation 
of each model’s coefficients, displayed in table 6.11, shows that in no circumstance was length 
of disease a significant coefficient. Age again suggested a decrease in the rate-of-change as a 
function of time, being a significant coefficient in 3 of the 5 models for which age was 
included. Sex was only included as a coefficient in the inferior nasal region of both eyes but 
showed a mixed effect on the rate-of-change and in neither circumstance was this significant.  
Modelling with the macular volume data produced no significant age or length of disease 
predictors, but followed the trend seen in RNFL data where both caused a decrease in the 
annual reduction. Sex did however produce a significant coefficient in the right eye (OS: 0.053, 
p=0.1; OD: 0.046, p<0.05) but in both eyes showed females as having a reduced rate of 
reduction year on year, thus indicating that men have a more aggressive thinning of their RNFL 








Adjusted R-Squared value for models with and without influential points 
 OS OD 
 Raw data Remodelled data Raw data Remodelled data 







Global 0.084 <0.001 0.089 <0.01 0.07 <0.01 0.049 <0.05 
Temporal 0.064  <0.01 0.05 <0.05 0.033 <0.05 0.038 <0.05 
Temporal 
Inferior -0.006 0.57 -0.004 0.44 -0.007 0.66 -0.009 0.80 
Temporal 
Superior 0.028 <0.05 0.014 0.11 0.018 0.08 0.012 0.13 
Nasal 0.036 <0.05 0.032 <0.05 0.028 0.07 0.042 <0.05 
Nasal 
Inferior 0.053 <0.05 0.06 <0.05 0.08 <0.01 0.09 <0.01 
Nasal 
Superior 0.026 <0.05 0.038 <0.05 0.053 <0.05 0.041 <0.05 
Macular 
Volume  0.071 <0.01 0.064 <0.01 0.083 <0.01 0.068 <0.05 
Table 6.8: P-value and adjusted R-squared values produced when remodelling RNFL 
thickness and macular volume data produced from longitudinal analysis, with influential data 
points removed. OS = left eye, OD = right eye 
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  Results for linear regression remodelling of longitudinal RNFL data 
  OS OD  














Disease -0.98 -0.97 <0.01 -0.77 -0.63 <0.05 
Age N/A N/A N/A 0.02 0.02 0.06 
Temporal Disease -0.8 -0.69 <0.05 -0.66 -0.58 <0.05 
Temporal 
Inferior Disease 0.3 0.42 0.44 -0.17 -0.09 0.80 
Temporal 
Superior Disease -1.01 -0.69 0.11 -1.02 -0.89 0.13 
Nasal 
Disease -1.2 -1.12 <0.05 -0.78 -0.74 <0.05 
Age N/A N/A N/A 0.02 0.03 0.07 
Nasal Inferior 
Disease -1.32 -1.19 <0.05 -1.06 -1.09 <0.01 
Age 0.04 0.05 <0.05 0.04 0.05 <0.01 
 Sex 0.9 0.93 0.18 N/A N/A N/A 
Nasal 
Superior 
Disease -1.11 -1.02 <0.05 -1.13 -1.06 <0.05 
Age N/A N/A N/A 0.024 0.02 0.24 
Macular 
volume 
Disease -0.047 -0.042 <0.01 -0.042 -0.039 <0.01 
Age N/A N/A N/A 0 0 0.63 
Sex N/A N/A N/A 0.022 0.02 0.19 
Table 6.9: Comparing the coefficient values and their significance from raw and remodelled 
data once influential data points have been removed. OS = left eye, OD = right eye 
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 Adjusted R-Squared value for three models 
 Length of disease, Age, Sex 
Length of disease, 
Age Length of disease 
Region OS OD OS OD OS OD 
Global 0.003 0.108* 0.01 0.12* 0.02 0.036 
Temporal -0.05 -0.041 -0.031 -0.024 -0.018 -0.006 
Temporal 
Inferior -0.03 -0.044 -0.035 -0.033 -0.017 -0.015 
Temporal 
Superior -0.001 -0.015 0.008 -0.011 0.026 -0.008 
Nasal 0.015 0.074 0.013 0.086* 0.029 0.033 
Nasal 
Inferior 0.007 0.156** -0.012 0.127** -0.016 0.008 
Nasal 
Superior -0.015 0.002 -0.002 0.02 0.013 -0.018 
Macular 
Volume 0.036 0.038 0 -0.022 0.008 -0.014 
p-values: * <0.05, **<0.01, ***<0.001  
Table 6.10: Adjusted R-squared values for models when using length of disease as a 
predictor and rate-of-change as the response variable. The model highlighted in grey for 






Results for linear regression models of longitudinal RNFL when using LoD as a 
predictor 
  OS OD  
Region  Coefficient p-value Coefficient p-value 
Global LoD 0.047 0.15 0.024 0.38 
 Age NaN NaN 0.041 <0.05 
Temporal LoD 0.002 0.94 0.028 0.41 
Temporal 
Inferior LoD 0.013 0.81 0.017 0.71 
Temporal 
Superior LoD 0.075 0.12 0.045 0.47 
Nasal 
LoD 0.102 0.1 0.035 0.34 
Age NaN NaN 0.045 <0.05 
Nasal Inferior 
LoD -0.024 0.75 0.019 0.64 
Age 0.058 0.18 0.063 <0.01 
Sex 1.725 0.16 -1.094 0.1 
Nasal Superior 
LoD 0.071 0.2 -0.019 0.63 
Age NaN NaN 0.042 0.08 
Macular 
Volume 
LoD 0.0015 0.47 0.0001 0.93 
Age 0.0012 0.30 0.0009 0.31 
Sex 0.053 0.1 0.046 <0.05 
Table 6.11: The coefficients created from using length of disease as a predictor of rate-
of-change of RNFL and macular volume data. OS = left eye, OD = right eye, LoD = 
length of disease  
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6.6.2 Longitudinal UWF-SLO 
Both arterial and venous data was evaluated with linear regression models so as to eliminate 
the possible effects of confounding predictors in the median rate-of-change analysis, but over 
the time scale for which data was collected no models were deemed significant in any region. 
As shown in tables 6.12 and 6.13, only negative adjusted R-squared values could be produced 
for 9 of the 16 vessel models, and where values were positive, they were still extremely small. 
Tables 6.14 and 6.15 display the coefficients produced from this analysis for arteries and veins 
respectively. For arterial data, disease had a negative coefficient in 5 of the 8 regions for which 
data was collected, with both the inferior temporal and superior temporal regions of the left 
eye showing disease to have no effect at all. Sex was included in 3 arterial models and had low 
p-values relative to other predictors, all with positive coefficients suggesting that being female 
has the net effect of thickening vessels year-on-year. Of the 3 models for which sex was 
included as a predictor for vein data, the effect of sex appeared to be reversed in two of the 
regions, showing females to have an increased prevalence of vessel thinning annually. As 
disease was not shown to have a significant effect in any region during regression analysis, 

















Adjusted R-Squared value for three models of longitudinal arterial data 
 Disease, Age, Sex Disease, Age Disease  
Region OS OD OS OD OS OD 
Temporal 
Inferior 0.001 -0.025 0.007 -0.017 -0.009 -0.006 
Temporal 
Superior -0.007 -0.011 -0.001 -0.015 -0.008 -0.008 
Nasal 
Inferior 0.013 0.044 -0.015 0.033 -0.005 -0.01 
Nasal 
Superior 0.009 -0.02 -0.012 -0.015 -0.009 -0.008 
 
Adjusted R-Squared value for three models of longitudinal vein data 
 Disease, Age, Sex Disease, Age Disease  
Region OS OD OS OD OS OD 
Temporal 
Inferior -0.01 0.013 -0.015 -0.011 -0.006 -0.01 
Temporal 
Superior 0.022 -0.014 0.014 -0.006 -0.004 -0.006 
Nasal 
Inferior 0.015 -0.01 -0.002 -0.014 -0.009 -0.007 
Nasal 
Superior -0.017 -0.008 -0.01 -0.004 -0.004 -0.006 
p-values: * <0.05, **<0.01, ***<0.001  
Table 6.12: Adjusted R-squared values of linear regression models when using rate-of-
change of arterial thickness as the response variable. The model highlighted in grey for 
each quadrant was selected for coefficient analysis OS = left eye, OD = right eye  
p-values: * <0.05, **<0.01, ***<0.001  
Table 6.13: Adjusted R-squared values of linear regression models when using rate-of-
change of vein thickness as the response variable. The model highlighted in grey for 





 Coefficients for linear regression models when using rate-of-
change of arterial width as the response variable  
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
Disease 0 0.99 -0.0017 0.53 
Age 0.0002 0.11 N/A N/A 
Temporal 
Superior 
Disease 0 0.97 0.0005 0.8 
Age 0.0001 0.18 N/A N/A 
Nasal Inferior Disease -0.0032 0.27 -0.0011 0.65 
Age -0.0001 0.62 -0.0002 0.05 
Sex 0.0062 0.09 0.0045 0.15 
Nasal Superior Disease -0.0001 0.95 -0.0006 0.73 
Age -0.0001 0.41 N/A N/A 
Sex 0.0042 0.08 N/A N/A 
 
 Results for linear regression model veins 
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
Temporal 
Inferior 
Disease -0.0017 0.51 -0.0006 0.81 
Age N/A N/A -0.0001 0.32 
Sex N/A N/A 0.0059 0.07 
Temporal 
Superior 
Disease -0.0009 0.75 0.001 0.57 
Age 0.0002 0.09 N/A N/A 
Sex -0.0045 0.17 N/A N/A 
Nasal Inferior 
Disease -0.0014 0.46 0.0015 0.56 
Age -0.0001 0.23 N/A N/A 
Sex -0.0034 0.12 N/A N/A 
Nasal Superior 
Disease -0.0016 0.44 -0.0011 0.45 
Age N/A N/A -0.0001 0.27 
Table 6.15: Coefficient values and their associated p-values when modelling vein width 
data produced from follow-up analysis.  OS = left eye, OD = right eye  
Table 6.14: Coefficient values and their associated p-values when modelling arterial 
width data produced from follow-up analysis.  OS = left eye, OD = right eye  
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6.6.3 Longitudinal visual acuity  
As seen in table 6.16, no model was significant and very little of the data’s variance was 
described by any of the models created as demonstrated by low adjusted R-squared values. 
Right eye data were best described by a univariate model of disease alone for both HCVA and 
LCVA, whereas left eye data was better described with a combination of the variables age and 
sex. Despite selecting the models with the highest adjusted R-squared value, none of the 
coefficients created for either eye was deemed significant (see Table 6.17). The coefficients 
of disease created for HCVA were the same for each eye, with a reduction of 2 letters per year 
attributable to disease.  
LCVA score appeared to increase by 2 letters per year in both eyes, as a consequence of MS. 
As with the models themselves, no predictor was found to be significant. Age had the effect of 
increasing HCVA each year as a function of time, but the opposite effect in LCVA. Sex was 
seen to have the largest effect of any predictor, being responsible for a five-letter reduction 





Adjusted R-Squared value for three models of HCVA and LCVA data 
 Disease, Age, Sex Disease, Age Disease  
Region OS OD OS OD OS OD 
HCVA -0.002 -0.01 0.01 -0.006 0.008 0 
LCVA 0.009 -0.018 -0.012 -0.005 0 0.004 
p-values: * <0.05, **<0.01, ***<0.001  
Table 6.16: Adjusted R-squared values for models when using HCVA and LCVA as the 
response variable. The model highlighted in grey for each eye was selected for coefficient 




6.7 Summary  
Direct comparisons of each group’s rate-of-change data was inconclusive as to the effects of 
MS on vessel width over time. In no region was rate-of-change of vessel width significantly 
different between the MS and HV groups, however significant differences were found between 
them when comparing data collected from OCT. Linear regression modelling did suggest a 
degree of accelerated vessel thinning in participants with MS but was not conclusive and 
RNFL data was in-line with previously reported rates-of-change when modelled. Although the 
lack of observed annual thinning seen in vessel width data may be due to an underpowered 
study or changes too small to resolve over the scanning period, it may also be because vascular 






 Coefficient results for linear regression models of HCVA 
and LCVA data   
  OS OD  
Region  Coefficient  p-value Coefficient p-value 
HCVA 
Disease -2 0.18 -2 0.32 
Age 0.07 0.28 N/A N/A 
LCVA 
Disease 2 0.35 2 0.26 
Age -0.03 0.76 N/A N/A 
Sex -5 0.1 N/A N/A 
Table 6.17: Coefficient values and their associated p-values when modelling HCVA and 





This study not only reproduces results which have previously been reported on the reduction 
of RNFL thickness and macular volume in patients with MS, but provides the first evidence 
of changes to the retina’s peripheral vasculature caused by MS. This discovery may lend 
credence to the theory that MS is first caused by an inflammatory response of the blood vessels 
in the brain. This chapter discusses the results presented in the preceding chapter, highlighting 
the strengths and limitations of the study described throughout this thesis. 
7.2 Study participants  
The number of individuals with RRMS far exceeded those of any other subtype. This was 
likely due to the nature of progressive subtypes and the opportunistic recruitment strategy 
employed in this study; patients frequenting the clinic were more likely to be receiving 
treatment and in need of regular review. As progressive subtypes do not currently have any 
form of effective disease modifying treatment, patients available for recruitment were more 
likely to have RRMS for which there are some therapies. Another likely cause is that 
Fingolimod (a second line therapy that can be prescribed to RRMS patients) has macular 
oedema listed amongst its possible side effects. Subsequently, individuals prescribed 
Fingolimod undertook baseline and follow-up OCT scans throughout their treatment as a 
precautionary measure to identify any signs of oedema. These individuals would already be 
familiar with part of my scanning procedure or would have to undertake scanning as part of 
their patient-centred care, so may have been more comfortable with participating in the study. 
Despite previous studies reporting that different MS subtypes have a different rate and profile 
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of thinning of the RNFL, subtype was not integrated into the regression models created for 
this study due to the overwhelming dominance of RRMS patients in recruitment numbers (88) 
(89). More targeted participant recruitment would aid future investigations into the differences 
in retinal anatomy between disease subtype, but this less-opportunistic approach would likely 
result in a lower rate of recruitment and need more time to reach its objectives than my study.  
As mentioned in Chapter 4, not all participants received follow-up retinal scans and of those 
that did, not all of the scans were of a sufficiently high quality for analysis. HVs received fewer 
follow-up scans than those in the MS groups. This is likely because MS participants adhered 
to their scheduled clinical appointments more fervently, the clinic sessions being focused 
around their medical wellbeing rather than being purely research related. Scheduling follow-
up scans for HVs required a greater degree of organisational effort to encourage people back 
to the clinic, whilst some HVs moved to locations too far away to reasonably travel back to 
the clinic for follow-up. 
7.3 OCT 
Although this study has lower participant numbers compared to larger investigations into the 
effect of MS on the retina, the results resonate with the changes previously reported in the 
literature. Differences seen between the MS groups and the HVs were great enough as a 
percentage of overall RNFL thickness/macular volume that our participant numbers had 
adequate power to often provide statistical significance with both Students t-tests and Mann-
Whitney U tests. This was also true of the MS (ON) group, which saw the greatest difference 
in RNFL thickness despite a lack of normality and low participant numbers (N<11).  Temporal 
regions showed the greatest difference but all regions except the inferior nasal showed a 
significantly thinner RNFL in the MS (no ON) group when compared to HVs. Global 
differences (OS: -10µm, p<0.001; OD: -11µm, p<0.001) were consistent with a large multi-
centre study of 414 MS patients, although was larger than that reported by a recent systematic 
review and meta-analysis which saw a 7.41µm thinner RNFL in 4109 eyes (90) (29). The 
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profile of differences seen, with greater reductions measured in the temporal regions of the 
retina, is typical of MS; thinning in the temporal region is the most reliable measure of both 
physical and cognitive disability in MS when compared to thinning in other quadrants (91). 
My results show a similar range of temporal RNFL thickness reduction (OS: -11µm, p<0.001; 
OD: -12µm, p<0.001) as presented by Antonio-Santos et al. (-11µm p<0.0001) and Henderson 
et al. (-12.8µm to -22.9µm) (92) (31).  
The reduced RNFL thickness in the left eye of MS (ON) participants was found to be larger 
than the global reduction reported by Petzold et al. in their meta-analysis of 2063 eyes (-24µm 
vs -20.1µm respectively), although the difference was not as large in the right eye (-16µm) 
and this meta-analysis was focused on changes measured with TD-OCT devices (27). As 
reported by Costello et al. the effect of ON is compounded after repeated attacks in the same 
individual, and with such small numbers of participants comprising the MS (ON) group in this 
study, individuals who have suffered from ON on more than one occasion could skew the data 
to a large extent (93). Likewise, this may also help explain the difference seen between the left 
and right eyes in the median analysis; with N<10 for both eyes, a lack of intraocular correlation 
is not unexpected.  By studying the historical correspondence of those in the MS (ON) group 
and incorporating the number of ON episodes for each eye into a regression model, this data 
could be better characterised and potentially explain the interocular variations that were 
observed. Despite these small numbers, in all regions except the inferior temporal the 
difference in median RNFL thickness was found to be significant when compared to that of 
HV’s. A significant reduction in macular volume was also observed in MS (no ON) 
participants when compared to HVs, with left eye data correlating well with Burkholder’s 
reported 10µm reduction in RNFL thickness for every 0.2mm3 reduction in macular volume 
(30).  
Linear regression modelling went on to suggest that the majority of the differences seen 
between the groups were due to disease rather than age or sex, although in some models these 
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predictors were also significant. Initially the MS and HV groups had relatively even 
demographics, which may explain why linear modelling showed similar results to the direct 
comparisons of each group’s average RNFL thickness or macular volume. However, having 
split the MS group into MS (no ON) and MS (ON), it was still vital to model the data to be 
sure of the role disease played in explaining the differences between the groups. Although the 
low adjusted R-squared values produced when modelling OCT data may suggest the absence 
of one or more confounders from the models, reports for similar studies do not suggest any 
additional important predictors (35); all models were found to be significant (p<0.01), except 
when modelling the inferior nasal region of both eyes, indicating that the models had 
descriptive value with disease being the most consistently significant predictor. Scatter plots 
such as the one displayed in Graph 7.1 suggest that a large variance within the datasets may 
be responsible for the low adjusted R-squared values presented in this thesis.  
The general lack of predictive power when using length of disease, age and sex as predictors 
of MS (no ON) data may be due to the huge variability in disease progression that is found 
between individuals with MS; length of disease is not a particularly reliable measure of disease 
activity because MS does not follow a single pattern of progression over time but is widely 
variable between patients and disease subtypes (3). Without regular MRI scans with which to 
view new/active plaques on the brain, or regular EDSS/MSFC assessments to quantify disease 
progression, such a predictive model would be difficult to create. A study which used said 
measures found a reduced rate of axonal thinning is associated with “no evidence of disease 
activity” in patients with MS, indicating that the rate of thinning is dependent on the disease 
status of an individual (94). Including EDSS/MSFC assessments into the retinal scanning 
sessions would provide informed data which may be useful for linear regression modelling, 
but it would also extend the sessions by a considerable amount of time at the inconvenience 








































































































Longitudinal data provided less conclusive results in assessing the rate-of-change of RNFL 
thickness and macular volume when using unpaired samples Student’s t-tests. This is likely 
due to the effect size being much smaller; comparing results at baseline will show compounded 
differences which have occurred year-on-year, whereas annual changes are both smaller and 
more susceptible to small changes caused by erroneous segmentation. Changes which occur 
over these time periods may also be smaller than the resolution of the device used to capture 
images (i.e. 7µm axial resolution for SD-OCT devices vs 1.1-2.9µm reduction in global RNFL 
thickness every 2 years), resulting in only extreme changes being detected or considered 
clinically significant. The low rate-of-change values seen suggests that the pace with which 
anatomical changes occur in the retina is slow (approximately 6-7 years for a measurable 
change), regardless of disease status. Large IQRs indicate a high variability in the rate at which 
changes occur between participants of the same group, with some participants having negative 
rates-of-change and thus thinning over time, whilst others have a thickening. This variation is 
visualized in Graph 7.2, which displays a box plot of the median annual rate-of-change in 
RNFL thickness seen in each group for left eye data; the participants from the MS (no ON) 
group appear on average to have either no annual change or an annual rate of thinning. Results 
which suggest a thickening were unexpected as even in HVs, annual thinning of the RNFL 
and loss of macular volume may be anticipated as a result of aging (36). However, the changes 
associated with age may again be too small to accurately measure with the resolution of the 
device used, and the data may represent the normal range of variation in retinal anatomy 
expected from multiple images acquired in different sessions. 
These results did not concur with those found in the literature relating to the annual change 
expected in RNFL thickness as measured in longitudinal analysis (see chapter 2) (33) (34) 

















































































the studies used TD-OCT to collect data which lacks the resolution and hence resolving power 
of SD-OCT to measure small changes and has a lower inter-rater and test-retest reliability (42) 
(35). One of these studies did however report a similar reduction in macular volume annually 
as found in the MS (no ON) group from this study (35). In the third study, which used a 
SPECTRALIS device and had a high number of RRMS patients, separate analysis of 
individuals with a clinical history of ON was not carried out, although no significant difference 
was found in participants who had previously suffered ON when compared to those who had 
not (33). My results conflict with this finding, with the annual rate of thinning being largest in 
the MS (ON) in 75% of circumstances. This would suggest that not only does RNFL thinning 
occur each time an individual suffers from ON, but that the effects of ON continue over time 
as patients have an increased rate of RNFL thinning.  
The likeliest reason for my results differing from those reported elsewhere and, in some cases, 
indicating a thickening of the RNFL is the low number of scans (in some cases as few as two) 
taken during the course of the study. Such subtle changes to RNFL thickness over a two-year 
period will be unsubstantial in comparison to the errors in segmentation or limitations of the 
device’s resolution. As such, in circumstances where there are just two scans for a participant 
the longitudinal results would be easily skewed by small errors This is despite the 
SPECTRALIS having good repeatability and ICC measures as discussed in chapter 3. Without 
being able to extend the study time (to increase the measurable change in RNFL thicknesses), 
one solution would be to take many more scans throughout the two-year period in order to 
create a more accurate gradient of change. This would require more of a patient burden and 
perhaps discourage individuals from participating in the study. Therefore, a more preferable 
potential solution would be to scan the eye multiple times using the OCT device during each 
session and average the scan results for each individual (supposing the scans are of sufficient 
quality). This would lead to greater accuracy, results which are less prone to error and therefore 
provide a more reliable source for rate-of-change. 
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Results from my linear regression analysis were closer to those reported by other longitudinal 
studies (33) (34) (33). My results suggest that age-related thinning of the RNFL occurs at a 
greater pace annually when individuals are younger and gradually slows over time. They also 
indicate that the median rate-of-change presented might be affected by some confounding 
variable in the HV group, as rates-of-change were found to be positive on average indicating 
a thickening of the RNFL over time rather than a thinning due to age. Such a missing 
confounder may not be restricted to just HV data, as the coefficients of disease estimated by 
the models created here are larger than the median rates-of-change calculated for the MS (no 
ON) group. 
The adjusted R-squared values when using length of disease as a predictor were once again 
low with only 3 models being significant, all of which were in the right eye (global, nasal and 
inferior nasal). The subsequent estimation of each model’s coefficients shows that in no 
circumstance was length of disease a significant coefficient. However, in all but two models 
the coefficient was positive which suggests, much like age, that the annual rate of RNFL 
thinning associated with MS (no ON) occurs at a greater rate early in the disease course and 
plateaus over time. The decline in the rate of thinning found in right eyes in this study is similar 
to that reported by Balk et al, although the left eye was found to have a larger decline in the 
rate of thinning year-on-year in the global region (33).  
7.4 UWF-SLO 
Differences were seen when comparing baseline vessel width (within 6.5 and 8.5 optic disc 
radii from the centre of the optic disc) from HV and MS (no ON) groups providing evidence 
to confirm hypothesis 1, although the degree of change was dependent on the region from 
which measurements were taken. Most notably, vessels in the nasal quadrants of the retina 
seem most effected in the MS (no ON) group, being the only region that saw significant 
differences in vessel thickness. The location of the greatest vascular differences between these 
two groups is not the same as changes seen in the RNFL data. This may be because blood 
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vessels in the temporal region form a more complex network with a greater amount of 
bifurcations and vessel crossings as capillaries supply a rich quantity of oxygenated blood to 
the macular. Such a complex network might lead to more errors in the segmentation of blood 
vessels and may therefore cover up any subtle changes in vessel width. On the other hand, the 
differences between retinal quadrants may be an accurate representation of 
anatomical/pathological changes which occur within specific locations of the retina. Despite 
the pattern of differences, in the majority of quadrants, despite a lack of significance, both 
arteries and veins appeared to have a slightly reduced width in the MS (no ON) group when 
compared to HVs. Although no other study has investigated the retinal vasculature in 
peripheral regions as this one has, the reduced vessel widths measured here is complimentary 
to Bhaduri’s study of blood vessels in close proximity to the OD (40).  
Evidence of an effect was not found when comparing the HV group and the MS (ON) group.  
With the relatively small differences expected in vessel width compared to the changes seen 
in RNFL thickness, along with the very low numbers of participants with a clinical history of 
ON (N<10), statistical tests applied to MS (ON) would likely lack meaningful power or 
reliability. Regardless, the results seem to resonate with what has been previously reported in 
the literature (40), although it has also been reported that blood flow is reduced specifically in 
the optic nerve head region in patients with a clinical history of ON (40) (95). This finding 
may not translate to peripheral regions of the retinal vasculature. 
My linear regression analysis seemed to further highlight the effect of MS on vessel width 
whilst considering age and sex as confounders. In arterial data, modelling generally showed 
slightly smaller effect sizes attributable to disease than when directly comparing the MS (no 
ON) and HV groups. This was not the case for the inferior nasal region, which saw disease 
bearing a greater effect in the linear models. Age, which was a significant predictor in the 
superior temporal and inferior nasal quadrants (when included in the models) was also 
negative in most cases, suggesting that vessels get thinner as one gets older. The modelling of 
vein data showed little change to the results from a direct comparison of the MS (no ON) and 
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HV groups, which may be because age does not appear to play the same role in the thinning 
of veins as it does with arteries (never being a significant predictor). Although the differences 
in vessel thickness were seen to be significant in some regions, it should be noted that even 
the greatest difference seen between the participant groups was smaller than the resolution of 
the imaging device used, as reported by the manufacturer (7µm difference found between HV 
and MS (no ON) groups in the inferior nasal quadrant vs a smallest resolvable object of 14µm). 
This would limit the current ability of UWF-SLO to create screening procedures for individual 
patients. Nevertheless, over a study population of 144 participants the compounded effect of 
vascular change provides new insight into how the peripheral vasculature changes in patients 
with MS. 
The disparity between the raw-data and remodelled coefficients of disease, especially those of 
the arterial dataset show a degree of sensitivity to influential data points which was not present 
in the RNFL regression models. This is likely due to the effect size in retinal vessels being 
smaller than that of RNFL thickness measures; with low numbers of participants, influential 
data points will have an exaggerated effect on the regression models. However, the disease 
coefficients still suggest that MS (no ON) does show a reduced retinal blood vessel thickness 
when compared to HVs. In order to determine whether this effect is progressive and occurs at 
a certain rate throughout the disease, the MS (no ON) data was once again modelled separately.  
Modelling of the MS (no ON) group when using length of disease as a predictor alongside age 
and sex showed a mixed effect attributable to length of disease. This may be due to the small 
effect sizes seen in the vessel width data in the MS (no ON) group, as well as the flawed 
assumption that length of disease is an accurate measure of disease severity. On the other hand, 
this modelling could suggest that changes to vessel anatomy occur early in the disease course 
along with initial inflammatory responses within the brain; the initial breach of the BBB may 
be mirrored in the BRB, and the inflammatory effects of this may cause an immediate 
reduction in blood vessel width. 
 128 
Longitudinal analysis showed no consistent trends when comparing the rate-of-thinning of 
vessels of the three groups through unpaired samples Student’s t-tests.  Similarly, no 
regression models were found to be significant when attempting to describe the data and the 
resulting adjusted R-squared values were extremely small. This may indicate that linear 
regression was an inappropriate tool for explaining variations in the data and more complex 
approaches are needed. This was supported by the lack of normal residuals produced from the 
models. However, upon examining the coefficients themselves: although direct comparisons 
between the participant group’s median annual change in vessel thickness showed little sign 
of individuals with MS having an increased rate-of-thinning, linear regression analysis 
indicates this might be masked by confounding variables, as was true of RNFL data. Disease 
shows an annual increase in the rate of arterial thinning in 5 of the regions modelled, with two 
regions showing no annual change. Likewise, modelling of vein data shows disease as causing 
an increased rate of vessel thinning in six of the eight models created, again in conflict with 
the results produced from directly comparing the three groups. Although none of the 
coefficients for any predictor were significant in this part of the analysis, this may well be due 
to a lack of power as changes in vessel width are small, there were low participant numbers, 
or the timescale was too short, rather than disease having no clear effect on the rate-of-change 
of vessel thinning.  Of the other predictors included, age had a mixed effect but produced a 
negative coefficient in six of the nine models for which it was included, suggesting that (unlike 
RNFL and macular volume) the rate at which age causes thinning of the vessels increases as 
individuals get older. 
7.5 Visual acuity 
Visual acuity is at present a widely used tool for determining the retinal function of an 
individual as it is quick, simple to understand and requires little expense. However, it can be 
difficult to create a controlled environment that is suitably consistent when undertaking 
testing, hence the large degree of change required before determining a drop of VA score 
which is of clinical significance. For example, though blinds were used to block sunlight 
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entering through the clinic window in this study, the level of illumination within the room 
would still vary to large amounts depending on the outside environmental brightness on any 
given day. In an ideal environment a constant level of illumination would have to be 
maintained to accurately compare participant scores. Secondly, social factors could potentially 
play a large role in how consistent each participant is in the effort and time they dedicate to 
providing an accurate VA score. Whereas retinal scanning mitigates this to some degree, VA 
is reliant on a participant trying their best to focus on the letters every time they are tested, 
which may conflict with their wishes should they be feeling rushed for time or tired. Despite 
these limitations, significant differences were seen between the three groups at baseline, as 
was expected.  
The reduction in HCVA found in the MS (no ON) group when compared to the HV group was 
above the 5-letter limit for clinical significance in the left eye, although right eye data only 
produced a 3 letter decline in score. While the difference between these two groups in HCVA 
was both significant and greater than 5-letters, in both eyes the fall in LCVA score narrowly 
missed the 7-letter drop to declare clinical significance. As mentioned, the highest scores were 
similar in both groups, however the scores in the MS (no ON) group had a larger range, thus 
indicating that although MS participants can perform well when viewing Sloan letter charts, 
they are more likely to have a low score than HVs. The lower median values seen in the MS 
(no ON) group correlates well with the reduction in RNFL thickness and macular volume also 
seen in this group. The large differences seen between the HV and MS (ON) group in RNFL 
thickness and macular volume were not reflected when comparing HCVA scores, with neither 
eye showing a significant difference despite a 9-letter decrease in median score for the left eye 
in the MS (ON) group. Left eye data was however significant when comparing LCVA scores, 
although the small drop in LCVA score for right eye data lacked evidence of an effect. The 
lack of evidence seen is likely due to the low participant numbers in the MS (ON) group as 
such large changes in RNFL thickness and macular volume would be expected to reduce the 
functionality of the retina.  
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The significant 5-letter reduction in HCVA score was also seen in both eyes when linear 
regression models were used to isolate the effect of disease. Despite the inclusion of age and 
sex as predictors, disease was the only coefficient to be significant, although the effect of age 
correlating inversely with retinal functionality was an expected phenomenon. Once again, 
LCVA score narrowly missed the 7-letter decline associated with clinical significance, 
although the coefficient was itself significant in both eyes. Surprisingly, length of disease 
proved to have a positive coefficient when used as a predictor for MS (no ON) data. Though 
this did lack significance, one would expect VA score to diminish with the length of time 
someone has lived with MS, however this result may yet again indicate the fallacious 
assumption that length of disease correlates with disease activity in MS.  
Follow-up data analysis, including regression models, produced mixed results. HCVA data 
saw a small annual decrease in score for the MS (no ON) group in both eyes, however both 
HVs and the MS (ON) group saw circumstances where an increase in HCVA occurred 
annually. Regression models did seem to indicate that MS was responsible for a 2-letter 
decrease in score year-on-year. LCVA score was found to conflict with the assumption that 
retinal function would diminish annually in MS participants, as regression models suggested 
LCVA to increase annually by 2 letters in MS. Age was also found to contribute to an increase 
in HCVA score annually, although the changes predicted were small. None of the models 
produced were significant. With the bar set high for a clinically significant change in both 
LCVA and HCVA score due to the nature of testing, it is unlikely that an individual would 
have such a dramatic reduction in their retinal functionality between scanning sessions unless 
they experienced an episode of ON. This analysis may therefore show the inappropriate nature 
of using rate-of-change as a method of determining drop-off in retinal functionality. Over a 
longer time period, a more comprehensive approach to the data may be to examine the 
percentage of each group that have a clinically significant change in their VA scores, as 
presented by previous research (see chapter 2). 
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7.6 Future work 
Vascular analysis in this study showed evidence that the blood vessels of the retina are 
anatomically altered as a consequence of MS, but to what extent is uncertain as this study was 
ultimately underpowered. Table 7.1 presents the power level for each of the vascular changes 
seen. Although differences between the HV and MS (no ON) groups were significant, none 
were above the 0.8 power threshold- arterial widths in the inferior nasal region of the right eye 
had the greatest power of 0.77.  
Future studies should be designed to confirm the differences seen at baseline between HV and 
MS (no ON) groups. Assuming the differences in vessel width seen are accurate, in order to 
prove statistically these differences, the numbers of participants needed for each of the four 
quadrants are shown in table 7.2, with power set to 0.8 and a significance level of 0.05. The  
 Power level when comparing the vessel widths of HV and MS (no 
ON) groups 
 Arteries Veins 
Quadrant OS OD OS OD 
Inferior Temporal 0.23 0.44 0.33 0.06 
Superior Temporal 0.093 0.11 0.17 0.05 
Inferior Nasal 0.62 0.77 0.60 0.47 




 Number of participants from both HV and MS (no ON) groups 
needed to create a power level of 0.8 when comparing vessel widths 
 Arteries Veins 
Quadrant OS OD OS OD 
Inferior Temporal 304 129 200 8172 
Superior 
Temporal 
1291 996 471 70332 
Inferior Nasal 66 56 72 123 
Superior Nasal 2739 241 276 192 
Table 7.1: Given the number of participants who had usable scans in each quadrant, the 
power level for both vessel classifications are presented for the effect size seen in this 
study 
Table 7.2: With power = 0.8 and significance = 0.05, the number of participants needed 
to provide evidence of change within each quadrant for the two vessel classifications are 
shown 
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number of participants needed to prove the findings in the inferior nasal quadrant of the retina 
are feasible, especially when comparing arterial widths. However, the numbers needed to 
provide evidence in the other quadrants are too large to reasonably expect to recruit. As such, 
future work using UWF-SLO imaging should focus on confirming the findings specific to the 
inferior nasal quadrant. The use of higher resolution imaging techniques (e.g., infrared SLO 
and fundus photography) may be able to discern changes in vessel thickness to a greater 
precision and thus confirm the reduction in vessel width seen in the other quadrants of the 
retina without such high participant numbers, although would struggle to image the peripheral 
retina. This higher precision may also be beneficial in identifying small changes which occur 
longitudinally throughout the disease course, and thus determine whether the vascular changes 
seen occur as a function of time. Incorporation of axial measurements should also be 
considered to improve accuracy of vessel width measures; when measuring the area of the 
Argus II retinal implant in vivo and comparing this to the known values, the accuracy of the 
measurement was 10.21% when axial length is unaccounted for and 1.93% when accounted 
for (65). Investigating vascular measures other than just vessel width (e.g., fractal dimension 
of the vascular branching pattern and vessel tortuosity) may also uncover differences between 
HVs and MS participants- pilot analysis could be completed on the data already collected in 
this study. To better understand the correlation of disease severity with anatomical changes in 
the retina, clinical information including EDSS/MSFC and MRI analysis would be a valuable 
asset in stratifying participants. 
Future studies should also be designed with a more proactive strategy for recruiting MS 
participants from each of the disease subtypes, as this would allow for better patient 
stratification and the potential for regression models that better describe the data. Models may 
also be improved by scanning participants at set intervals rather than relying on rate-of-change 
calculations. This would allow for a more direct comparison between the participant groups to 
be made. One of the limitations of this study is the small timescale over which scans were 
taken relative to potential length of the disease course (approximately 2 years vs median of 30 
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years between diagnosis and death), especially given the slow rate at which changes to the 
retinal anatomy appear to occur (6). By increasing the length of time over which data is 
collected, analysis may offer evidence of when vascular changes occur in the disease course- 
a question which should be central to future studies. Specifically, prospective investigations 
must look to determine whether changes occur over the entire disease course or are only the 
result of initial disease mechanisms. Collecting data over a longer timescale should not prove 
to be problematic for MS participants as the chronic nature of the disease requires regular 
consultations with a neurologist. However, recruiting HVs for the same length of time might 
prove more problematic as individuals may relocate or become unavailable for follow-up 
scans. One possible solution could be to more actively encourage the friends and family 
members of MS participants to volunteer as presumably they would remain committed to a 
study for a greater period of time. Linear regression models may however be less effective at 
describing longitudinal changes over larger timescales, as is shown by both length of disease 
and age causing a progressively smaller amount of thinning each year, suggesting that thinning 
plateaus over time. As such, more sophisticated statistical analysis is likely needed to 
characterise the data.  
An effort to fully automate vessel analysis in UWF-SLO images would be extremely beneficial 
in encouraging researchers to investigate changes to retinal vasculature. Despite its benefits, 
the analysis software used for this study does require a large investment of operator time which 
may discourage other clinicians and researchers. Automating vessel analysis would also 
increase the feasibility of using UWF-SLO devices as a screening tool for MS, and reduce 
experimental errors associated with human intervention. Ultimately, future work should be 
directed towards the creation of a screening method which can identify the early anatomical 
changes associated with MS and offer early intervention for those at risk of developing 
symptoms. Integrating all the vascular measures mentioned alongside information from OCT 
and visual acuity data could be a useful predictive tool for use in logistical regression models 
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The opening chapters of this thesis explained the importance of diagnosing and treating 
patients with MS as early as possible and how retinal imaging could be of benefit by providing 
a patient friendly tool for viewing the CNS and microvasculature. Building on the examples 
of previous studies which have touted retinal imaging as a potentially useful biomarker for 
disease progression, this longitudinal pilot investigation was designed to address the three 
hypotheses set out at the beginning of this thesis: 
1. An individual diagnosed with MS will have quantifiable differences to their retinal 
vasculature at baseline imaging compared to healthy controls 
2. An individual diagnosed with MS will have quantifiable differences to their RNFL 
thickness and macular volume as measured by OCT 
3. An individual diagnosed with MS will have quantifiable changes to their retinal 
vasculature which occur longitudinally and correlate with disease progression and 
worsening severity 
The novel discovery of evidence showing thinner blood vessels in the inferior nasal quadrant 
of the retina has shown that changes to the retinal anatomy are not exclusively 
neurodegenerative and therefore supports hypothesis 1. To ensure future studies are powered 
sufficiently and evidence can be gathered for the global differences seen, the power 
calculations included in chapter 7 should be used as an important guide for participant 
recruitment numbers. Much as changes to the RNFL and macular are deemed to be useful 
correlates for atrophy in the CNS, my findings could be indicative of vascular changes which 
occur to similarly sized vessels within the brain. The data collected can further be utilised to 
full effect, with additional analysis completed on vascular parameters such as tortuosity. This 
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would allow for a more comprehensive understanding of how the blood vessels change as a 
consequence to MS. 
In an attempt to place the vascular changes found into the context of neurodegenerative 
changes which occur at baseline and over the course of the disease, my study provides 
important replication of the results from other research using OCT in MS. The evidence shown 
of reduced RNFL thickness and macular volume in patients with MS addresses and confirms 
hypothesis 2. Baseline data was more conclusive than longitudinal data, most likely because 
the changes expected over an approximately 2-year period are too small to be reliably 
measured with the number of participants in this study. However, the trend seen in linear 
regression modelling shows results which are similar to those found in the literature and 
suggests that neurodegenerative changes occur gradually over time. If possible, future studies 
should organise for participants to have follow-up scans no less than 6 years from baseline as 
this would allow for measurable differences in RNFL thickness to occur, given the rate-of-
change predicted by linear regression modelling.  
Finally, hypothesis 3 was addressed when analysing longitudinal UWF-SLO data. Unlike 
OCT, evidence of a longitudinal effect on vessel thickness was not found, which may either 
mean that the changes occurring over the period of this study were too small to be measured 
by the currently available devices, or that changes to the retinal vasculature do not occur 
longitudinally but over a short period of time early in the disease course. Discovering which 
of these is true should be a motivation for future investigations; if changes to the vasculature 
only occur early in the disease course, they could be used as a screening tool for MS before 
the onset of debilitating symptoms. Secondly, if these changes occur prior to changes to the 
RNFL and macular, then it would support the premise that inflammation strikes before 
neurodegeneration, helping us a gain a deeper insight into the disease and how it may be 
treated. Hypothesis 3 could be better examined in prospective studies by utilising an effective 
measure of disease severity, such as EDSS or MSFC, as length of disease has been shown 
throughout this study to be an ineffective measure of disease activity.  
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In conclusion, scanning the retina with different imaging modalities has shown promise to 
become an effective clinical tool for revealing information about MS, specifically pertaining 
to neurodegeneration in OCT and microvascular changes in UWF-SLO. The methods 
presented in this thesis may help expand the understanding of the initial disease mechanisms 
in MS, but also the development of future screening methods which identify patients with MS 
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